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Chapter I 
Introduction 

For more than 25 years the loop diuretic furosemide is prescribed for edematous states 
associated with congestive heart failure, hepatic or renal failure or nephrotic syndrome. 
Since the introduction of furosemide, its pharmacokinetic and pharmacodynamic 
properties, adverse reactions and interactions have been well documented in both 
volunteers and patients with specific diseases. Much of this literature was reviewed by 
Benet, Cutler, Hammarlund and Ponto [1-5]. However more research is still going on to 
explore further details of its diuretic properties. In particular, little is known about the 
maximal effective dose in patients with congestive heart failure or the most efficient mode 
of administration. 
Furosemide 
Furosemide is an anthranilic acid derivative highly bound to serum protein (98-99%). 
It is a high-ceiling diuretic agent which is delivered to its site of action by active secretion 
via the nonspecific organic acid pump of the proximal tubule. It acts in the luminal 
membrane of medullary and cortical aspects of the thick ascending limb, including the 
macula densa cells in the early distal tubule [6]. The exact mechanism of action is not fully 
understood but the drug is believed to act by inhibiting the active reabsorption of chloride at 
the luminal surface of the ascending limb of the loop of Henle, indirectly preventing 
reabsorption of sodium which passively follows chloride [7-9]. The ensuing natriuretic 
response is related to the concentration of the drug in the urine at the active site and 
describes the configuration of a classic sigmoid shaped log dose-response curve. 
Approximately 50-70% of an intravenous dosage and 25-30% of an oral dosage will 
actually be available at the site of action. This general finding is altered by factors which 
influence the biovailability and/or urinary delivery of the drug. 
The total amount of drug that reaches the urine and the time course of delivery of drug 
into the urine are important determinants of diuretic response [10]. In addition, the diuretic 
response is determined by the filtration capacity of the glomeruli and the shape of the dose-
response curve. The latter parameter is influenced by sodium reabsorptive forces in other 
nephron segments. This in turn is determined by several disease states or pharmacologic 
therapy. All determinants are summarized in table I. 
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Table I. Determinants of response to loop diuretics 
Total amount of drug reaching the unne 
Dose 
Biovai lability 
Capacity for secretion in the proximal tubule 
Time course of drug delivery into the unne 
Filtration capacity of glomeruli 
Sodium reabsorpuve activity of other nephron segments 
e g. - congestive heart failure 
- nephrotic syndrome 
- cirrhosis 
- Secondary to drugs 
- NSAID's 
- Adaptation to chronic diuretic therapy 
Diuretics and congestive heart failure 
In the last thirty years diuretics have formed the mainstay of pharmacological therapy 
for congestive heart failure. Given the fact that sodium retention at renal level is the first 
manifestation of left ventricular failure, it is a logical step to interfere with this mechanism 
[11]. Sodium retention occurs as a result of a number of neurohumoral mechanisms, in 
order to preserve circulatory homeostasis. Commonly used diuretics in the treatment of 
heart failure are thiazides and loop-diuretics. Thiazides are mild diuretics which are active at 
the cortical diluting segment of the loop of Henle and the distal collecting tubule (in this 
segment approximately 3-5% of the filtered sodium load is absorbed). They become 
ineffective as the glomerular filtration rate falls below 30 ml/min. The most effective 
diuresis is realized with loop diuretics such as furosemide, bumetanide, piretanide and 
ethacrynic acid that inhibit chloride/sodium cotransport in the ascending limb of the loop of 
Henle, where approximately 25 percent of the filtered sodium load usually is absorbed. 
Although an even greater fraction of the filtered load (70-80%) is absorbed in the proximal 
tubule, diuretic agents (e.g. acetozalamide) that exert their action in this part of the tubule 
effect only a moderate diuresis, because sodium ions which are rejected proximally have 
ample opportunity to be reabsorbed at more distal loci in the nephron. 
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Alternative pharmacological approaches in the treatment of patients with congestive 
heart failure are therapy with arterial and/or venous vasodilators, angiotensin converting 
enzyme (ACE) inhibitors or positive inotropic agents. There are few studies companng the 
efficacy of diuretics with these alternative treatments. In a double blind study in patients 
with mild heart failure, Cowley et al. compared an increment of the dosage of diuretics with 
the addition of Captopril [12]. Both treatments improved symptom limited exercise 
tolerance, but a higher dose of furosemide proved to be more effective. In another double 
blind study Richardson et al. compared Captopril alone with furosemide in combination 
with amiloride [13]. They found that angiotensin converting enzyme inhibition alone is an 
insufficient treatment for patients with mild heart failure and a history of overt pulmonary 
edema. Within this context it is interesting that it is reported that in normal subjects, given 
Captopril alone, even sodium retention may occur [14]. Few studies exist on the interaction 
of diuretics and ACE-inhibitors in CHF patients with respect to diuretic dosage. It seemed 
that in severe chronic heart failure Captopril does not have a diuretic sparing effect and these 
patients require the original dose of diuretics to obtain an improvement in symptoms [15]. 
Studies investigating the influence on survival of treatment with ACE-inhibitors or 
with hydralazine combined with isosorbidedinitrate both in combination with diuretics and 
digoxin in patients with CHF classification II-IV according to the New York Heart 
Association (NYHA) have shown to prolong life [16-19]. 
Finally, with respect to diuretics as a single therapy, it should be mentioned that there 
is no good evidence in the literature to support the strong clinical impression that diuretics 
improve functional status in patients with heart failure. On the other hand it is unlikely that 
any long term study of diuretic therapy versus placebo in heart failure would be presently 
jugded ethically acceptable [20]. 
Absorption of furosemide in congestive heart failure 
It has been postulated that in patients with congestive heart failure changes in intestinal 
motility and perfusion, slow gastric emptying and intestinal edema cause a diminished drug 
absorption [21]. This in tum could diminish diuretic effects after oral furosemide 
administration. Most studies on this subject compared furosemide pharmacokinetics in 
patients with stable congestive heart failure with those in healthy volunteers. Brater et al. 
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have shown that patients with congestive heart failure have a reduced sensitivity to 
furosemide after one single oral dose. In this study, patients with CHF excreted less 
furosemide into the urine after both oral and intravenous doses compared to normal 
subjects, which proved that the decreased elimination after oral doses was not due to a 
decreased absorption in CHF patients.[22]. In another study absorption kinetics and 
phannacodynamics of furosemide (40 to 160mg) were investigated in patients with CHF 
during chronic medication. Chatuverdi et al. found that drug excretion-response curves 
were lower and shifted to the right compared to data obtained from healthy volunteers [23]. 
Moreover, in this study a clockwise hysteresis, that was earlier demonstrated in healthy 
volunteers, was evident indicating acute within-dose tolerance [24]. Acute diuretic tolerance 
is presumably caused by compensatory renal sodium retention because it occurs in 
response to excessive sodium excretion and correlates with both the rate and the magnitude 
of diuresis. Altogether, the main reason for a decreased effect in these patients is a 
pharmacodynamic resistance and not an impaired delivery of furosemide to the site of 
action [3]. 
Until now, only one study was published in patients with CHF, in which pharmaco-
kinetics and pharmacodynamics of the decompensated state was compared with the 
compensated state [25]. In this study, different oral doses (40-160 mg) of furosemide were 
compared and it was demonstrated that there was an alteration in furosemide absorption in 
decompensated congestive heart failure. A 57 % decrease in lag time, a 27 % decrease in 
time to peak serum concentration and a 29 % increase in the peak serum furosemide 
concentration in compensated as compared to decompensated patients was found. However 
no significant change was seen in absorption or elimination half-lives and area under the 
serum concentration versus time curves for furosemide. These findings suggest that the rate 
rather than the extent of absorption is affected. In addition, the authors found an 
unexpected slight decrease in responsiveness when the patients where compensated. 
Further studies are warranted to assess the relative contributions of various 
pharmacokinetic and pharmacodynamic factors to furosemide resistance and to clarify the 
mechanisms of resistance. 
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Maximal furosemide dose in end stage renal failure as model for severe 
congestive heart failure 
The furosemide dose usually recommended for the treatment of congestive heart failure 
consists of 40 to 120 mg/day, with a maximum single oral or intravenous dose of 200 to 
250 mg [26]. Little is known about the maximum effective dose that can be given safely to 
patients with congestive heart failure. More experience on this subject has been obtained in 
patients with end stage renal failure [27-29]. In these patients maximum doses of 2000 mg 
seemed both effective and safe. So far, there are no studies available on the diuretic efficacy 
and limitations of high dose furosemide in end stage renal failure in patients on 
haemodialysis with some residual diuresis. 
As stated above, few studies have investigated the effects of high dose furosemide in 
patients with refractory congestive heart failure [30]. However, because severe congestive 
heart failure is often accompanied by renal impairment, it seems a logical step to treat these 
patients with higher furosemide doses than generally advocated. 
Efficiency of furosemide 
Some earlier observations have provided more insight in diuretic efficiency of 
furosemide. When oral administration of furosemide 40 mg was compared with an 
intravenous bolus of the same dose in healthy volunteers the diuretic efficacy of 
intravenous administration seems to be higher. However, there was a discrepancy between 
overall response relative to amounts of drug reaching the active site [10]. In other words, 
using the same dosage the relation between the cumulative natriuresis and total urinary 
furosemide excretion differed when the drug is given orally compared with intravenous 
administration [31, 32]. In a cross-over study Wilson et al. compared once daily 
administration of 40 mg furosemide with 20 mg twice daily in healthy volunteers. They 
demonstrated a greater efficacy when furosemide was administered twice daily [33]. In 
another cross-over study in healthy volunteers the diuretic effects of orally administered 
furosemide 40 mg was compared with the same dosage after pretreatment with probenecid. 
In this study probenecid, that influences the secretion of furosemide at the level of the 
7 
proximal tubule, increased the overall natriuretic response from 262 ±16 mmol/Sh to 358 ± 
11 mmol/Sh, while the total amount of furosemide delivered into the urine was identical in 
both groups. Since dose-response curves were identical, this effect did not occur because 
of changed sensitivity of the nephron to furosemide. As a consequence the only factor 
which could account for this difference in response was a changed time course of delivery 
of furosemide into urine. In other words, the time course of furosemide delivery into the 
proximal tubule seems an important determinant of diuretic response. Diuretic efficiency is 
defined as the optimal dose-response relationship. So, theoretically, continuous exposure 
of the renal tubules to furosemide, which could be attained by using a continuous infusion, 
would lead to a greater diuretic efficacy than bolus administration. 
Diuretic resistance 
Most patients with CHF do respond to the generally recommended therapeutic doses 
of potent diuretic drugs. However some patients are refractory and diuretic resistance 
ensues. In literature there is not a clear definition of diuretic resistance. In general, diuretic 
resistance is defined as an inadequate response to conventional diuretic therapy. Before 
concluding to this diagnosis all correctable causes of diuretic resistance have to be excluded 
[34, 35]. Firstly, dietary restrictions must be checked by measuring 24h urinary sodium 
excretion and corrected when needed. In addition, patient compliance with diuretic therapy 
has to be reaffirmed, if necessary checked, and interactions with agents known to interfere 
with sodium excretion have to be excluded (e.g. NSAID's). 
Table II summarizes single patient observations as well as some larger studies in 
patients with severe congestive heart failure who were treated with furosemide and were 
supposed to be diuretic resistant. Maximal furosemide doses that were given at the moment 
that other treatment was started, were 1000 mg intravenously and 500 mg orally. At that 
moment alternative treatment was started to obtain an edema-free state. 
What is the cause of diuretic resistance ? 
In a recent paper. Loon et al. have discussed some mechanisms of diuretic resistance 
[44]. During prolonged furosemide therapy a reduced response was seen despite a well-
maintained GFR. This could not be ascribed to 1) a reduced response in the loop of Henle, 
2) altered furosemide kinetics, 3) decreased delivery of NaCl to the loop of Henle or, 
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Table II. Maximum furosemide dose in patients with severe CHF before the start of 
additional therapy (e.g. hemofiltration, combination therapy with thiazide). 
Author 
Gunstone, 1971 [36] 
Epstein, 1977 [37] 
Rimondini, 1987 [38] 
Simpson, 1987 [39] 
Bamford, 1982 [40] 
Aravoi, 1989 [41] 
Kiyingi, 1990 [42] 
Channer, 1990 [43] 
η 
12 
1 
11 
9 
1 
12 
17 
10 
NYHA 
? 
IV 
IV 
IV 
IV 
IV 
IV 
m-iv 
max furosemide dose 
160-240mg, p.o. 
160mg p.o., b.i.d. 
180-300mg i.v. 
160-1000mg i.v. 
500mg p.o. 
160-300mg p.o. 
200-500mg p.o. 
120mg i.v. 
? 
other medication 
spironolactone 
digox in 
digoxin 
spironolactone 
digoxin, Captopril 
spironolactone 
nitrates 
Captopril, digoxin 
warfarin 
Captopril, nitrates 
prazosin 
? 
additional 
therapy 
metolazone 
metolazone 
hemofiltration 
hemofiltration 
metolazone 
metolazone 
metolazone 
dobutamm 
bendrofluazidc 
4) hyperaldosteronism, but to an enhanced sodium reabsorption in the distal tubule. This 
enhanced capacity of the distal convoluted tubule to reabsorb sodium, following adaptation 
to furosemide therapy could account for the finding of an enhanced response to 
chlorothiazide injection during furosemide infusion in hypertensive patients receiving 
furosemide therapy. These findings may provide a rational basis for the use of thiazide and 
loop diuretic combinations in the treatment of patients with severe edema, resistant to high 
doses of loop diuretics alone. 
Diuretic alternatives in the treatment of diuretic resistant congestive heart 
failure 
Diuretic resistance seems to represent a final manifestation of congestive heart failure. 
Patients resistant in this way have a poor prognosis and often a very poor quality of life. 
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Various treatment modalities are available, such as dobutamin infusion [45, 46], 
hemofiltration [38, 39, 47], continuous ambulant peritoneal dialysis [48] and when 
possible, cardiac transplantation [49]. All above mentioned treatments have their own, 
sometimes life-threatening, side-effects. The following different diuretic alternatives in 
these patients deserve consideration, in view of the data shown by Loon et al [44]. 
Firstly, combination with diuretics that exert their action in another part of the nephron 
tubule is an option. The use of thiazides is based on the principle of sequentional nephron 
blockade [50]. There is some experience with the use of thiazides in combination with loop 
diuretics [36, 37, 40-43, 51]. When doing so a vigorous diuresis can ensue but severe 
hypokalemia and circulatory collaps may occur [35,42]. 
A second approach to diuretic resistance is the use of continuous furosemide infusion. 
Constant diuretic infusion limits the ability of the kidney to retain NaCl and theoretically a 
greater natriuresis in otherwise resistant patients could be achieved. In patients with end 
stage renal failure and in healthy volunteers continuous infusion seems more effective than 
bolus administration [52, 53]. In addition, continuous infusion would provide a relatively 
constant diuresis, instead of the peak and trough that are seen during oral or intravenous 
bolus therapy. Secondly, this mode of administration would allow rapid termination of an 
undesirably vigorous diuresis. Thirdly, there is little risk of toxic serum levels because, 
although cumulative doses are high, hourly furosemide administration is relatively low. 
Although often advocated, there is a lack of studies that investigated diuretic efficacy of 
continuous furosemide infusion in patients with CHF and diuretic resistance. 
Potassium and magnesium in relation with furosemide 
The therapeutic use of furosemide is known to result in increased urinary excretion of 
potassium and magnesium. Because furosemide exerts its main action in the ascending part 
of the loop of Henle, where most of the magnesium (65%) is reabsorbed, we have to keep 
in mind that furosemide is liable to produce magnesium deficiency. However, in most 
patients the serum concentrations of these electrolytes are often not correlated with the 
intracellular contents [54, 55]. Long term treatment with diuretics, especially in 
combination with other magnesium lowering factors, such as the use of digitalis, 
inadequate dietary intake, hyperaldosteronism, and high alcohol intake can cause overt 
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hypomagnesia [56-58]. This in turn may stimulate ventricular ectopic activity and 
contribute to sudden cardiac death [59, 60]. Gottlieb et al. demonstrated that patients 
suffering from heart failure with hypomagnesia had more frequent ventricular premature 
complexes and episodes of ventricular tachycardia than did patients with a normal serum 
magnesium concentration [61]. Even though both groups were similar with respect to 
severity of heart failure and neurohumoral variables, patients with a low serum magnesium 
concentration had a significantly worse prognosis during long-term follow-up. Because 
most patients with congestive heart failure use diuretics there is a potential risk of 
hypokalemia and hypomagnesia. 
To prevent hypokalemia and hypomagnesia induced by diuretics, treatment with 
potassium-/magnesium-sparing agents, such as triamterene, amiloride or spironolactone is 
advised rather than oral potassium/magnesium suppletion. Triamterene and amiloride 
inhibit sodium-potassium exchange by a non aldosterone-dependent mechanism and 
manifest activity within hours of their administration. Alternatively, spironolactone which 
acts via inhibition of aldosteron action requires two to four days to achieve maximal 
effectiveness. In addition, the diuretic and antikaliuric effect of spironolactone depends on 
the presence of aldosterone. All three potassium-sparing agents are very weak diuretics if 
used alone but are supposed to have potassium- as well as magnesium-sparing effects. 
However, combination with loop diuretics could attenuate the potassium and magnesium 
sparing effects of these agents. With respect to triamterene there are conflicting results 
about its magnesium-sparing properties in combination with furosemide. The effectiveness 
of addition of triamterene to thiazides in preserving the cellular content of potassium and 
magnesium is well documented [62]. However, there are no studies on the magnesium 
sparing effects of triamterene in combination with furosemide. 
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The purpose of the studies reported in this thesis was to investigate the 
following questions 
1. Is diuretic resistance in patients with congestive heart failure due to alterations in 
furosemide pharmacokinetics ? 
2. Is diuretic resistance in patients with congestive heart failure due to alterations in 
furosemide pharmacodynamics ? 
3. Is high dose furosemide effective in the treatment of patients with severe congestive 
heart failure ? 
4. Is high dose furosemide effective in the treatment of hemodialysis patients with residual 
diuresis ? 
5. Is there a difference in pharmacodynamics comparing bolus versus continuous 
administration of furosemide ? 
6. Can diuretic resistance be managed by using continuous infusion of furosemide ? 
7. Is addition of triamterene to furosemide useful with respect to the presumed potassium 
and magnesium sparing properties of triamterene ? 
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Summary 
To investigate the influence of the presence of oedema on the pharmacokinetics and 
pharmacodynamics offurosemide we selected 9 hospitalized patients (mean age 70.3 yrs, 
range 59-84 yrs) with severe congestive heart failure (NYHA III to IV) and an assessed 
amount of peripheral oedema of at least 5 kg. In these patients the absorption of a single 
oral dose of 250 mg of furosemide was studied when their heart failure was 
decompensated and again, after intensive therapy, when it was clinically compensated. 
The mean (±SEM) weight loss after clinical treatment was 12.0 ±2.2 kg. Individual 
furosemide plasma concentration-time curves could be adequately fitted to a one-
compartment model with 1 first-order absorption and elimination process, in which 
absorption took place in 2 fractions with different lag times. Comparing the 
decompensated state with the compensated state we did not find significant differences in 
pharmacodynamics, absorption half-life, elimination half-life, time to peak serum 
concentration, peak serum concentration itself and area under the plasma concentration 
time- curve. However, the relative amount offurosemide absorbed in the firs ¡fraction was 
significantly increased after compensation. 
We conclude that the presence of massive edema in patients with congestive heart failure 
has a minor influence on pharmacokinetics and pharmacodynamics of high dose oral 
furosemide. 
Introduction 
The diuretic efficacy of furosemide in patients with severe congestive heart failure 
(CHF) appears to be unpredictable, especially after oral administration. Alterations in both 
pharmacokinetics and pharmacodynamics have been reported to influence the diuretic effect 
in these patients (Andreasen & Mikkelsen 1977; Brater et al 1980; Greither et al 1979; 
Kelly et al 1977). Previous studies suggest that malabsorption of furosemide, secondary to 
changes induced by CHF, could be a cause of diminished response (Benet et al 1976). 
Edema of the gut wall, delayed gastric emptying, decreased intestinal motility or 
decrements in splanchnic flow have all been reported to contribute to the reduced 
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absorption of furoscmide. Most studies investigating furosemide pharmacokinetics have 
been done in patients with stable, compensated CHF and in those cases a normal 
bioavailability of furosemide was observed compared with healthy volunteers (Brater et al 
1982; Greither et al 1979). More recent studies show alterations of furosemide 
pharmacokinetics in patients with CHF compared with normal volunteers (Brater et al 
1984). These changes in the absorption profile probably contribute to the rather erratic 
réponse of orally administered drug (Chatuverdi et al 1987; Vasko et al 1985). In these 
studies different low doses of furosemide were compared; the main objective of the current 
study was to find out whether the disease state influenced the absorption of higher dosages 
of furosemide in severe CHF. Therefore, the pharmacokinetics and pharmacodynamics of 
an oral dose of 250 mg of furosemide were studied both in a state of CHF with massive 
oedema (decompensated) and again after intensive diuretic therapy in a state with negligible 
oedema (clinically compensated). 
Patients and methods 
After approval of the protocol by the local ethical committee, we selected 9 hospitalized 
patients with severe, right (and eventual left) sided CHF (classes ΠΙ to IV according to the 
New York Heart Association) of different origin associated with an assessed amount of 
peripheral oedema of at least 5 kg. The relevant patient characteristics are shown in table I. 
Their mean age was 70.3 years (range 59-83) and their mean weight was 72.9 kg (range 
44.3-106.5 kg). The patients underwent a physical examination, complete blood count, 
electrocardiogram and a chest X-ray and all gave their written informed consent prior to the 
start of the study. Before entry to the study all patients were on maintenance therapy with 
furosemide using dosages ranging from 80 to 160 mg a day. The last oral dose of 
furosemide was administered 24h before the start of the study. 
The study protocol consisted of two study days. On the first day patients were 
decompensated with an assessed amount of at least 5 kg of oedema, whereas the second 
study day was planned when the patients were clinically compensated. On the first study 
day after an overnight fast each patient received a tablet containing furosemide 250 mg 
(Lasix®, Hoechst). After succesful treatment, when clinically compensated and free of 
oedema, patients again received furosemide 250 mg after an overnight fast. Treatment to 
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obtain an oedema-free state mostly consisted of intensive diuretic therapy with schedules of 
continuous intravenous administration of furosemide up to 160 mg/h. Continuous 
intravenous furosemide medication was stopped 12h before oral administration of 
furosemide on the second study day. Physical examination was daily carried out by the 
same physician. Additional medication (e.g. digoxin, Captopril) was permitted and not 
changed on the study days. All patients were confined to bed during both study days. 
During their stay in the hospital all patients received a diet containing sodium 80 mmol 
and potassium 100 mmol each day. Total daily fluid intake was limited to 1500 ml. On the 
two study days plasma samples were drawn via an intravenous catheter at 0, 15, 30, 45, 
60, 80, 100, 120, 150, 180, 240, 360, 480, and 720 minutes after oral administration of 
furosemide. The blood samples were centrifuged and the plasma was separated and stored 
at - 20oC in the dark until the furosemide concentration was analysed. In addition, a venous 
blood sample was taken on both study days before furosemide administration for 
determination of electrolytes, bicarbonate, urea, creatinine, albumin, plasma renin activity 
(PRA) and plasma aldosterone. Urine samples were collected half-hourly till 6h after 
administration, then from 6-8, 8-12 and 12-24h and carefully protected from light. Aliquots 
of the urine samples were assayed immediately for sodium, potassium, chloride, albumin 
and creatinine content and the rest of each sample was frozen for later analysis of 
furosemide concentration. For pharmacodynamic comparison with our patients with CHF, 
we also present the pharmacodynamic data of 6 healthy volunteers. The protocol for these 
subjects has been described previously (van Meyel et al 1990). Their age ranged from 19 to 
21 years and their weight from 64.7 to 87.9 kg. All volunteers had a normal medical 
history, physical examination, complete blood count and biochemistry. After oral 
administration of furosemide 40 mg, urine was collected on the treatment day at intervals 0 
to 1, 1 to 2, 2 to 3, 3 to 4, 4 to 6, 6 to 8, 8 to 12 and 12 to 24h after the dose. Urine was 
analysed for sodium, potassium, creatinine and furosemide. 
Analysis of plasma and urine 
The concentrations of furosemide in plasma and urine were assayed by a method, 
recently developed in our laboratory (Rüssel et al 1989). In brief, extraction of furosemide 
and the internal standard desmethylnaproxen (DMN) was achieved using bonded silica 
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sorbent. Plasma (0.5 ml) was mixed with 50% (w/w) urea to denaturate proteins; 
subsequently 0.01 M potassium citrate buffer (pH 3.0) was added and the sample was 
loaded onto a 'C 1 8 Bond Elut' extraction column. Urine (0.05 ml), diluted to 0.5 ml with 
phosphate buffer (pH 6.8), was handled in essentially the same way. The column was 
washed with potassium citrate buffer 0.01mol/L (pH 5.0); furosemide and DMN were 
eluted with a mixture of methanol : НаНСОз 0.01 mol/L solution (1:1), 10 μΐ of which 
was injected into the liquid Chromatograph. High performance liquid chromatography 
(HPLC) was performed on a 'LiChrosorb RP-IS' (5цт) column with a mobile phase 
consisting of 48 parts methanol : 52 parts phosphate buffer 0.02 mol/L pH 3.0 (48:52) 
delivered at 1 ml/min and fluorescence detection (excitation wavelength 275 nm, emission 
400 nm). The recovery of furosemide and DMN was virtually complete (>95%) and 
independent of concentration with an intra-assay coefficient of variation between 1.8 and 
3.2% in plasma and between 1.1 and 2.9% in urine at a furosemide concentration of 
0.021-52.5 μg/ml The detection limit is 5 ng in 0.5 ml of biological sample (0.01 μg/ml). 
Routine blood chemistry was measured by autoanalyzer. Plasma aldosterone and PRA 
were determined by radio immuno assay (de Man et al 1980; Drayer & Benraad 1975) 
Data analysis 
Because of the irregular absorption profile of furosemide it was not possible to fit the 
curves according to the usual compartment models with simple continuous first order 
absorption. When the absorption process was divided into 2 distinct periods, each with the 
same absorption rate but with a different lag-time and using a 1-compartment model, a 
good description was possible. According to this model a part of the dose is almost 
immediately available for absorption (short lag-time), while the remaining part becomes 
available later. Rate-limited absorption (flip-flop) kinetics was assumed. In addition, this 
model takes into account the furosemide plasma concentration at the start of the study. 
The plasma furosemide concentration vs time data of the i-th fraction of the dose 
absorbed was calculated as 
0,(1) = А;*[ехр(- (t - t lagl)ka} - exp(- ( t - t ^ y k j ] (i = 1 or 2) 
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F Xi. k
a 
where A.
 = 
VdflCepk.) 
Here к, is the rate constant of absorption, k,., is the rate constant of elimination, t]ag. is the 
lag time of the i-th fraction, X; is the furosemide amount absorbed in the i-th fraction, F is 
bioavailability and Vd is volume of distribution. 
Assuming that F and Vd for both fractions are the same, the relative amount of furosemide 
absorbed in the first fraction (faj) was calculated as 
A! 
f a ^ 100% 
А ^ А г 
Total individual plasma concentrations after oral administration of furosemide were 
described with the following set of equations 
0 < î <tU g l C(t) = C0*exp(-t.kel) 
tiagi < » < tug2 C(t) = Co*exp(-t.kel) + C^t) 
t >tlag2 C(t) = Co*exp(-t.kel)+ €,(1) + €2(1) 
where Q, is the initial plasma concentration. The area under the plasma concentration-time 
curve (AUC) was calculated by integration of C^t) + СгСО, after extrapolation of the 
terminal phase of the plot to infinity. Half-lives of absorption and elimination were obtained 
from their respective rate constants. Data analyses were carried out using the NONLIN 
computer program (Metzler et al 1974) in which data were weighted reciprocally (1/C). The 
accuracy of fit to the plasma concentration data was evaluated through the deviations 
between observations and model predicted values expressed as 
R2=l-Z(Dev)2/Z(Obs)2 
where Z(Dev)2 is the sum of squared deviations and Z(Obs)2 is the corrected sum of 
squared observations. 
The diuretic effect was measured as the sodium excretion rate and was plotted as a function 
of the logarithm of the urinary excretion rate of furosemide. 
Statistical analysis was performed using Student's t-tests for paired data at the 5% 
significance level. We corrected for 9 pharmacokinetic parameters with multiple 
comparisons according to Bonferroni. The results are expressed as mean ± SEM, unless 
indicated otherwise. 
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Results 
Figure 1 shows the individual plasma furosemide concentration-time curves of the 9 
patients in the decompensated and the compensated states. After clinical treatment weight 
loss averaged 12.0 ± 2.2kg (table I). The time between the two study days was 15.4 ± 2 
days. The mean endogenous Creatinin clearance ((Χς;
Κ
) was reduced (51 ± 9 ml/min, 
range 14 to 106 ml/min). The patient (#3) with the lowest CLCR, showed the highest 
furosemide plasma concentration. The values of CLçR on the first and the second study 
day were almost equal, except in one patient (#1) in whom an apparent decrease in С 1 ^
к 
of almost 50% was observed. This was most probably caused by inadequate urine 
sampling during the last interval (8-24 hr). We calculated that the CLÇR of this patient on 
the next day was 46 ml/min. Individual pharmacokinetic parameters are presented in table 
II. The data for the patients were best fitted using a discontinuous absorption model both 
during decompensated (r2 = 0.987 ± 0.003) and compensated states (r2 = 0.983 ± 0.006). 
There appeared to be no significant difference between the total amounts of furosemide 
absorbed (AUC), the time to peak serum concentration and the peak serum concentration 
itself, between the 2 states. However, when comparing the first absorption fraction (as a 
percentage of total absorption AUC) of the patients in the decompensated state with that of 
the compensated state, we found a significant difference. In the decompensated state the 
first absorption fraction (fa^ was smaller than in the compensated state (31 ± 8% vs 65 ± 
8%, ρ = 0.0055). The Vd in 5 patients was higher when their CHF was decompensated, 
but no correlation was observed between the amount of weight loss and Vd, even in the 
patient (#8) with the largest weight loss. As stated above flip-flop kinetics were assumed, 
even for the patient (#3) with the lowest CL C R (14 ml/min) in whom elimination is 
probably the rate limiting step. As shown in table III there was a trend towards greater 
furosemide excretion during the first 2h after oral furosemide administration when CHF 
was compensated. Yet, this higher excretion seems to have no influence on the natriuretic 
effect and volume excretion during this period. 
The relationship between log furosemide excretion rates and sodium excretion rates is 
shown in figure 2. Since it was not possible to obtain adequate urine collections in all 
patients, the data from only 7 patients are included in this figure. A comparison of the 
pharmacodynamics between the 2 study days revealed no significant differences. The dose-
response curves of these patients show a shift downward and to the right when compared 
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Table I. Characteristics of patients with congestive heart failure in the decompensated state. 
Pt 
no. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
Mean 
SEM 
Age 
ω 
78 
59 
83 
67 
59 
73 
59 
73 
82 
70.3 
3.3 
Sex 
M 
M 
M 
F 
M 
F 
M 
F 
M 
Weight 
(kg) 
68.9 
82.5 
44.3 
53.0 
106.5 
62.4 
92.4 
66.3 
79.6 
72.9 
6.4 
Weight 
decrease 
(kg) 
5.0 
10.0 
8.1 
5.7 
14.2 
12.3 
20.0 
24.8 
7.5 
12.0 
2.2 
CLçRa (ml/min) 
sttidy 1 
52 
23 
14 
47 
106 
64 
65 
45 
41 
51 
9 
study 2 
29 
32 
12 
48 
107 
66 
58 
44 
50 
50 
9 
NYHA 
class 
Ш 
IV 
IV 
Ш 
IV 
IV 
Ш 
IV 
IV 
Diagnosis 
CAD 
CC 
CAD 
CAD 
PH 
CAD 
CP 
CAD 
CAD 
Doseb 
(mg) 
80 mg 
120 mg 
120 mg 
120 mg 
80 mg 
80 mg 
160 mg 
160 mg 
120 mg 
Additional 
medications 
С, D.Th 
С, D, К. I 
D.K 
С, D, K.T 
D.K 
D.K, Th 
D.K.Th 
A, D.K 
С. D.A 
a For values m L/h, multiply by 0.06 
b Last oral dose of furosemide 
Abbreviations CAD = coronary artery disease, CHF = congestive heart failure, PH = pulmonary hypenension; CP = cor pulmonale; A = acenocoumarol, С : 
D = digoun; I = isosorbide duutrale, К = potassium chloride, Τ = tolbutamide, Th = theofylline, F = female, M =male. 
Captopril; 
ro 
Figure 1. Individual plasma concentration vs tinte curves of patients with decompensated 
( · ) and compensated (O) congestive heart failure after oral administration offurosemide 
250 mg. 
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Table III. Excretion offurosemide and sodium into urine, and urine volume in 7 patients with congestive heart failure when decompensated 
and compensated (mean ± SEM) over time фег oral administration offurosemide 250 mg. 
Time Furosemide (mg) Sodium (mmol) Volume (ml) 
(h) 
decompensated compensated decompensated compensated decompensated compensated 
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
- 0.5 
• 1 
- 1.5 
- 2 
- 2.5 
- 3 
- 3.5 
- 4 
0.2 
1.2 
2.1 
4.2 
5.3 
4.9 
5.1 
5.3 
± 
± 
± 
+ 
+ 
± 
± 
± 
0.1 
0.5 
0.6 
0.8 
0.9 
0.5 
0.8 
1.1 
0.9 
3.2 
4.3 
5.5 
6.0 
5.8 
5.5 
5.3 
± 
± 
± 
± 
± 
± 
± 
± 
0.4 
2.2 
1.9 
2.3 
1.9 
1.5 
0.8 
1.1 
0.6 
2.3 
7.9 
13.1 
7.8 
8.5 
11.6 
11.7 
± 0.3 
± 1.0 
± 3.1 
± 4.8 
± 2.6 
± 3.4 
± 3.5 
± 3.9 
1.2 
3.3 
9.9 
10.2 
7.8 
8.1 
8.1 
7.3 
± 
+ 
± 
± 
± 
+ 
+ 
± 
0.4 
1.0 
4.4 
3.6 
2.5 
2.4 
2.5 
2.5 
25 
63 
115 
159 
114 
115 
131 
130 
± 
+ 
+ 
± 
± 
± 
+ 
± 
10 
16 
36 
50 
27 
34 
33 
37 
45 
102 
140 
129 
114 
110 
111 
99 
± 12 
+ 29 
± 44 
± 40 
± 22 
± 26 
± 27 
± 25 
Total (0-24) 81.1+ 9.2 90.0 ± 10.8 118.1 ± 38.0 84.0 + 23.4 2250 ± 460 2040 ± 360 
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Figure 3. Sodium excretion rate (μπιοΙΙηύη) versus time in 7 patients with congestive heart failure of ter oral 
administration offurosemide 250 mg. 
Table IV. Mean (±SE) biochemical parameters and 24h urinary excretion of 
electrolyte and furosemide in patients with decompensated and compensated 
congestive heart failure (n = 9). 
DECOMPENSATED COMPENSATED 
Furosemide excretion, mgl24h 
Sodium excretion, mmol/24h 
Potassium excretion, mmoll24h 
Creatinine clearance», mllmin 
Serum sodium, mmolll 
Serum potassium, mmolll 
Serum albumin, gli 
Serum creatinine, iimolll 
Serum urea, mmolll 
Serum bicarbonate, mmolll 
Aldosterone, nmolll 
Renin, nmolll/h 
74.5 
119 
64 
51 
135 
4.2 
34.7 
116 
11.8 
28.7 
1.1 
11.8 
+ 
± 
± 
± 
± 
± 
+ 
± 
+ 
+ 
± 
+ 
10.5 
38 
7 
9 
1.6 
0.3 
2.2 
13 
1.6 
1.6 
0.6 
4.3 
82.4 
84 
80 
50 
136 
4.4 
35.3 
120 
15.1 
29.7 
1.8 
17.3 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
+ 
12.3 
23 
14 
9 
1.2 
0.2 
2.3 
16 
2.5 
2.0 
0.5 
2.1 
8
 For value in L/h, multiply by 0.06. 
with the mean pharmacodynamic data obtained from 6 healthy volunteers. Figure 3 shows 
the sodium excretion rates vs time plots of these 7 patients. Table IV presents the 
biochemical parameters used to assess the hydration state of the 9 patients, such as serum 
sodium, serum urea, serum albumin and serum bicarbonate. These parameters were almost 
equal during the two study days; urinary electrolyte and furosemide excretions also showed 
no significant differences. 
Discussion 
A prominent finding of this study is that the large weight reductions in these patients 
showed only a slight association with changes in the pharmacokinetic parameters of 
furosemide when the two study days are compared, as shown in table II. Of course, this 
could be partly due to a type 2 error, because of the relatively small number of patients. 
This possibility is supported by Vasko et al (1985) who in a study of comparable design, 
observed a significant decrease in lag-time and time to peak serum concentration, and an 
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increase in the peak serum concentration in 11 patients when in compensated state as 
compared with the decompensated state. The mean weight decrease was 5.3 ± 0.6 kg and 
those investigators used different doses of furosemide (range 40 to 160mg). In our study 
the weight decrease was larger (12.0 ± 2.2 kg), which could expected to exert a greater 
influence on absorption pharmacokinetics, especially with regard to bioavailability. The 
availability of the orally absorbed furosemide determined by the percentage of the excreted 
dose in the decompensated patients in our study reached 27 ± 5% after 24h and is in 
agreement with data in the literature (Hammarlund-Udenas & Benet 1989; Ponto & 
Schoenwald 1990a). In the present study no influence in bioavailability was noticed when 
patients were in a compensated state (28 ± 7%). There is only one case report in which oral 
furosemide showed a very low bioavailability in the oedematous state (17.3%) compared 
with the oedema-free state (74.7%). However, it must be stressed that this patient did not 
suffer from CHF but from idiopathic oedema (Odlind & Beerman 1980). The availability of 
orally absorbed furosemide in a healthy volunteer ranged approximately from 20 to 55% 
(Ponto & Schoenwald 1990a). Thus, in patients with CHF the diminished diuretic efficacy 
of furosemide seems not caused by reduced bioavailability. 
Discontinuous absorption pharmacokinetics after oral administration of furosemide to 
patients with CHF, as observed in most of our patients, were reported earlier (Benet et al 
1976; Chatuverdi et al 1987). It is not easy to elucidate the cause of the discontinuous 
absorption. Delayed gastric emptying has been suggested as a cause, which in tum could 
be due to an increased sympathetic and reduced parasympathetic activity as described earlier 
in patients with CHF (Benet et al 1976; Benowitz & Meister 1976). Hence, it is possible 
that improvement in the state of compensation influences the speed of gastric emptying. In 
our patients we did observe a significant difference, comparing the first absorption fraction 
in decompensated and compensated states. In the majority of our patients fai was greater 
when their CHF was compensated. As a consequence, we did observe a trend towards a 
larger furosemide excretion during the first 2h after oral furosemide administation during 
compensation. However, this greater excretion seems to have no influence on the onset and 
quantity of natriuresis and volume diuresis. Consequently massive oedema in patients with 
CHF does not appear to be a cause of reduced absorption of furosemide, but of altered 
absorption. In addition, a change in the absorption profile of furosemide occurred when 
patients were in an oedema-free state. 
To obtain a negative sodium balance in our patients we increased the furosemide dose 
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between the two study days. In an earlier study we have shown that high doses of 
furosemide in patients with severe CHF are effective and result in minor side effects 
(Gerlag & van Meyel 1988). During the use of high doses of furosemide in the current 
study, patients underwent a daily physical examination by a specialist in internal diseases. 
No biochemical or clinical signs of dehydration or major adverse effects were observed in 
this period. This supports the statement of Anand et al (1989) that careful clinical 
assessment of patients by an experienced physician is a reliable method for preventing 
diuretic-induced dehydration. 
As shown in the dose-response curves, there were minimal pharmacodynamic changes 
between the decompensated and compensated states. However, it must be stressed that the 
pharmacodynamics of furosemide are markedly diminished in patients with both 
decompensated and compensated CHF compared with data obtained from healthy 
volunteers. The pharmacodynamic data of our volunteers are in close agreement with data 
from the literature, supporting the changes in pharmacodynamics of furosemide between 
healthy subjects and patients with CHF. It is suggested that in patients with cardiac failure 
the reduced renal blood flow (which causes an increase in sodium reabsorption at the 
proximal tubule and/or distal nephron) is an important factor in the development of a 
diminished response to loop diuretics (Ponto & Schoenwald 1990b). Consequently, 
diuretic resistance in patients with CHF seems to be determined by changes in 
pharmacodynamics. Whether the patient with CHF is in a compensated or decompensated 
state appears to have a minor influence on the pharmacodynamics of furosemide. Together 
with this we found discontinuous absorption pharmacokinetics, which are influenced by 
the disease state in patients with CHF. However, this factor has only a minor effect on the 
onset and magnitude of the diuretic action, comparing the decompensated and compensated 
states. 
We conclude that the pharmacokinetics and pharmacodynamics of high dose 
furosemide in patients with CHF and massive oedema show minor alterations after clinical 
treatment to an oedema-free state. 
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Summary 
Thirty-five patients with severe chronic congestive heart failure that was refractory to 
conventional therapy were given high dosages offurosemide (250-4000 mgld) because of 
significantly reduced renal function (mean endogenous creatinine clearance, 0.53 
mLlsll.73 m2 [32 mLi'mini'1.73 m2}. Natriuresis, weight reduction (mean, 11 kg), and 
relief of symptoms were achieved in all patients. The mean survival after the start of the 
high-dose furosemide therapy was 11.3 months (range, 0.5-36 months)(n=35). When this 
therapy eventually failed, long-term intermittent hemofiltration was performed in eight 
selected cases, further prolonging survival (mean, 3.0 months). High dose furosemide 
therapy and hemofiltration improved the quality of life and prolonged survival. The use of 
diuretics in congestive heart failure should therefore include treatment with high-dose 
furosemide, which is effective and can be given over a long period without serious side-
effects. 
Introduction 
Chronic congestive heart failure is a common terminal manifestation of heart disease. If 
there no precipitating cause to be cured, only symptomatic therapy remains. This comprises 
restriction of physical activity, reduction of preload by dietary salt restriction and diuretics, 
enhancement of myocardial contractility by positive inotropic agents, and reduction of 
afterload by vasodilators or angiotensin-converting enzyme inhibitors. If these measures 
fail to induce normal, edema free circulation, then flebotomy, thoracocentesis and 
ultrafiltration may be attempted with hemodialysis, hemofiltration of peritoneal dialysis [1]. 
Diuretics are an important aid in the treatment of edematous states. The loop diuretics 
furosemide, bumetanide, and ethacrynic acid are the most potent of the available classes of 
diuretic agents, mediating the excretion up to 30% to 40% of the filtered sodium load [2]. 
The usual furosemide dosage recommended for management of chronic heart failure is 40 
to 120 mg/d, with a maximum single oral or intravenous dose of 200 to 250 mg [1]. 
In the treatment of edematous patients with moderately to severely impaired renal function 
due to chronic renal disease, high dosages of furosemide (250 to 2000 mg/d) have been 
found effective when lower doses failed [3]. These high doses can be given without fear of 
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major side effects. Otoxicity is rare and occurs only after rapid intravenous injection of high 
doses[4]. 
In chronic congestive heart failure, renal plasma flow is reduced. If the reduction is 
modest, then the glomerular filtration rate is preserved by efferent arteriolar constriction, 
resulting in normal levels of serum creatinine. In severe cases, however, renal plasma flow 
is markedly reduced and constriction of the afferent arterioles results in a reduced 
glomerular filtration rate with elevated serum creatinine levels [5]. 
We therefore studied the effects of high dose furosemide in patients with severe chronic 
congestive heart failure that was refractory to conventional therapy. When the edema 
proved resistant to this treatment, longterm intermittent hemofiltration, a dialysis mode 
characterized by great cardiovascular stability [6] was contemplated as a last resort. 
Patients and methods 
Thirty-five patients (13 female, 22 male) with refractory chronic congestive heart failure 
were treated with high-dose furosemide between March 1981 and April 1987. Relevant 
data are presented in Table 1. Most patients (n=32) were in class IV of the New York Heart 
Association classification at the start of the therapy, despite often extensive previous 
treatment, including furosemide treatment in doses up to 160 mg. Almost all showed 
symptoms of gross chronic edema. For ethical reasons, no control group could be formed, 
because survival was estimated to be a few weeks at best. Excluded from the study were 
patients with acute left ventricular failure or primary intrinsic renal disease (as judged from 
urinary sediment and the presence of proteinuria in the compensated state). 
A moderate reduction in salt intake (to between 80 and 100 mmol/d) was prescribed for 
most inpatients and all outpatients. For inpatients, the furosemide dose ranged from 250 to 
4000 mg/d, given intravenously in boluses (up to 1000 mg) or by continuous drip (up to 
4000 mg/d), or given orally. For the outpatients, treated orally, the maximum dose was 
2500 mg/d. 
The dose required to initiate natriuresis and reduce edema and bodyweight was 
determined empirically. The doses were doubled every 12 to 24 hours when given orally 
and every four to eight hours when given intravenously, until brisk natriuresis occurs. 
At the start of furosemide therapy, all other medication was continued, and bodyweight, 
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supine and standing blood pressures, pulse rate, and central venous pressure (determined 
by visual inspection of the neck veins [7]) were measured daily. Complaints and physical 
examination findings were also recorded. 
The total daily output of urine was collected for creatinine, sodium, and protein 
measurements. A chest roentgenogram and an electrocardiogram were obtained before the 
start of treatment and again before discharge from the hospital. Before and during the first 
days of high-dose furosemide therapy, serum sodium, potassium, chloride, bicarbonate, 
urea, creatinine, uric acid, and albumin values were determined daily, along with the 
colloid osmotic pressure (transudation phenomenon, 4400 colloidosmometer, Vescor). 
These measurements were continued until a compensated state without edema and with 
normal central venous pressure and stable serum urea and creatinine values was attained. 
The frequency of clinical and laboratory examinations was then reduced to twice weekly. 
At that time furosemide was given only orally. Discharge from the hospital was initially 
followed by weekly and later by monthly visits to the outpatient clinic. The same indicators 
of hydration status and effective circulating volume were measured at each visit. 
When furosemide was no longer effective despite increasing doses, the desirability of 
prolonging life was discussed with the patient, his or her relatives, and at least two 
internists or residents. When all agreed, furosemide therapy was terminated and long term 
intermittent hemofiltration (Fresenius Hemoprocessor, Sartorius filters) was started as a 
final resort [6]. Without hemofiltration the patient died. Vascular access was achieved by 
means of femoral vein catheterization, and an arteriovenous fistula for regular therapy if 
necessary. The follow-up period ended at death or in April 1987. 
Results 
The endogenous creatinine clearance was markedly reduced in many of the patients, 
with a mean of 0.53 ± 0.22 mL/s/1.73m2(32 ± 13 mL/min/1.73m2) (Table I). It was 
calculated from data collected during an edema free period (or when edema was least 
severe), which suggest that in several patients the creatinine clearance was even lower 
when high-dosage furosemide therapy was started, because of a lower cardiac output in the 
severely decompensated state (Fig 1). The ratio of serum urea nitrogen to creatinine at the 
start of the therapy was at least 20 in 21 patients (mean, 25 ± 11; range, 12 to 54 [normal 
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Figure 1. High-dose furosemide treatment (lOOOmgld, given intravenously) of chronic 
congestive heart failure in a 50-year-old man (patient 18) resulted in marked diuresis (urine 
volume [UV], 4 to 12 Lid), marked urinary sodium (US) excretion (in chosen scale, 
sodium excretion exceeded urine vollume on second day), reduction in bodyweight (BW) 
by about 20 kg in three days, and normalization of central venous pressure (CVP) (normal 
R-4 to 8 cm H2O). Renal function, as indicated by endogenous creatinine clearance (ECC) 
and serum creatinine (SCr) level showed distinct improvement until reduction of effective 
circulating volume occurred on March 22, whereupon furosemide dosage was reduced to 
250 mgld (given orally). UCr indicates urinary creatinine excretion per day. 
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Table ¡. Patients data 
Palienl/Sex/Age, y 
l/M/64 
2/F/63 
3/M/76 
4/F/81 
5/F/77 
6/F/75 
7/M/64 
8/M/52 
9/F/85 
10/F/81 
H/F/72 
12/F/86 
13/F/80 
14/M/65 
15/M/63 
16/M/76 
17/F/62 
18/M/50 
19/M/76 
20/M/61 
21/M/75 
22/M/71 
23/M/83 
24/F/84 
25/M/76 
26/M/84 
27/M/71 
28/F/87 
29/M/61 
30/M/75 
31/F/75 
32/M/86 
33/M/62 
34/M/58 
35/M/67 
Cause 
of 
Illness* 
CP 
CM 
CAD 
CAD 
CAD 
CM 
CAD 
CM 
CAD 
VD 
VD 
CAD 
CAD 
CAD 
CP 
CAD 
VD 
CM 
CAD 
CP 
CAD 
CM 
CAD 
CM 
CA 
CP 
CM 
CAD 
CM 
CM 
CP 
CAD 
CM 
VD 
CM 
Mean or total 13 F, 22 M/72 
Restriction 
¡nd 
Diuretics Digit 
+ + 
+ + 
+ + 
+ 
+ + 
+ 
+ + 
+ + 
+ + 
+ 
+ 
+ + 
+ 
+ 
+ 
-
+ + 
-
+ 
-
+ + 
+ + 
+ + 
+ + 
+ + 
+ 
+ + 
+ + 
+ + 
+ 
+ 
+ + 
+ + 
+ 
+ + 
+ 10 
Previous Treatment 
Salt 
ECC, 
mL/s/1.73 m2 
iuretics igitalis Vasodilatorst Captopril Dopamine (mL/min/1.73 m2)# 
SUN/Cr 
Ratio§ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
1.02 (61) 
0.43(26) 
0.33(20) 
0.45(27) 
0.35(21) 
0.27(16) 
0.48(29) 
0.37(22) 
0.48(29) 
0.67(40) 
0.35(21) 
0.83(50) 
0.35(21) 
0.43(26) 
0.87(52) 
0.23(14) 
0.57(34) 
0.93(56) 
0.40(24) 
0.37(22) 
0.50(30) 
0.43(26) 
0.53(32) 
0.53(32) 
0.47(28) 
0.55(33) 
0.30(18) 
0.68(41) 
0.33(20) 
0.18(11) 
0.98(59) 
0.47(28) 
0.93(56) 
0.75(45) 
0.67(40) 
0.53±0.22 (32±13) 
12 
17 
16 
29 
27 
22 
17 
48 
32 
25 
24 
20 
34 
53 
25 
16 
54 
13 
16 
21 
23 
36 
17 
23 
20 
16 
27 
26 
14 
30 
26 
41 
21 
24 
19 
25±11 
* CP indicates cor pulmonale; CM cardiomyopathy; CAD coronary artery disease; VD valvular disease. 
t Vasodilators included nitroglycerin, hydralazine, and prazosin. 
# ECC indicates endogenous creatinine clearance (normal, 1.75 to 2.42 mL/s/1.73 m2 [105 to 145 mL/min/1.73 m2]). 
§ SUN/Cr ratio indicates the ratio of the serum area nitrogen level to the creatinine level (normal, 10 to 15.1). 
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Table II. Results of high-dose furosemide treatment 
Patient 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
Mean 
Dose, 
mg/d 
500 
500-1000 
250-1000 
500 
250-500 
250-1500 
500 
500-1500 
500-lOuO 
500 
500-750 
250-500 
250-500 
250-1000 
500 
250-500 
500-750 
250-500 
250-500 
250-500 
250-1000 
250-2000 
250-500 
250-4000 
500-1500 
250-500 
250-2000 
500-1000 
1000-2500 
250-1000 
250-500 
250-1000 
500 
500 
500-4000 
Weight 
Reduction, kg 
18 
10 
7 
10 
15 
6 
6 
9 
8 
6 
18 
6 
3 
7 
18 
7 
10 
22 
4 
10 
20 
14 
10 
10 
19 
6 
13 
12 
10 
7 
21 
8 
17 
8 
6 
11.115.2 
Change in 
NYHA 
Class* 
І -П 
І -П 
Ш-П 
ΠΙ-Π 
І -ІП 
І -Ш 
iv-m 
І -ІП 
І -ІП 
IV-II 
І -ІП 
rv-in 
Г -ІП 
iv-m 
IV-II 
І -П 
Г -ІІ 
IV-II 
rv-in 
IV-II 
iv-ra 
iv-m 
Г -ІП 
г -ш 
Г -ІП 
г -ш 
Г -ІІ 
ΠΙ-Π 
IV-II 
І -Ш 
IV-II 
І -Ш 
IV-II 
І -П 
IV-II 
Survival 
Furosemide 
Treatment 
36 
6 
14 
1 
14.5 
8 
12 
26 
0.5 
7 
11 
10 
1 
33 
3 
16 
6 
19 
10 
22 
2 
6 
3.5 
10 
4 
16.5 
19 
14 
11 
1 
10 
2 
8 
8 
24 
11.3+8.9 
. months 
Hemofiltration 
. . . 
0.25 
. . . 
. . . 
1 
7.5 
5.5 
. . . 
3.5 
1 
0.5 
5 
. . . 
. . . 
3.0±2.6 
Uric Acid, 
mol/L 
(mg/dL)# 
610(10.3) 
510 
820 
780 
440 
750 
780 
480 
470 
340 
720 
410 
500 
530 
600 
520 
620 
650 
740 
660 
770 
540 
720 
630 
630 
590 
570 
680 
800 
610 
430 
640 
630 
660 
690 
(8.6) 
(13.8) 
(13.1) 
(7.4) 
(12.6) 
(13.1) 
(8.1) 
(7.9) 
(5.7) 
(12.1) 
(6.9) 
(8.4) 
(8.9) 
(10.1) 
(8.7) 
(ИЛ) 
(10.9) 
(12.4) 
(11.1) 
(12.9) 
(9.1) 
(12.1) 
(10.6) 
(10.6) 
(9.9) 
(9.6) 
(11.4) 
13.4) 
(10.3) 
(7.2) 
(10.8) 
(10.6) 
(11.1) 
(11.6) 
(10.4±2.0) 
Cause 
of 
Deatht 
MI 
AA 
Pneumoni 
MI 
Bleeding 
Ileus 
CHF 
CHF 
CHF 
CVA 
CHF 
CHF 
CHF 
CHF 
MI 
CHF 
Pneumoni, 
CHF 
MI 
MI 
GIH 
CHF 
CHF 
• · * 
CHF 
CHF 
* NYHA indicates New York Heart Association. 
# Uric acid in serum (normal for men, <420 nmol/L [<7.1 mg/dL]; normal for women, <340 μιηοΙ/L [<5.7 mg/dL]). 
t MI indicates myocardial infarction; AA, aortic aneurysm; CHF, chronic (congestive) heart failure; CVA, cerebrovascular 
accident; and GIH, gastrointestinal hemorrhage. 
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range, 10 to 15.1], indicating enhanced tubular urea reabsorption because of renal 
hypoperfusion [2]. 
Eighteen patients showed hyponatremia prior to high-dose furosemide therapy; the 
serum sodium level ( normally 138 to 144 mmol/L [138 to 144 mEq/L] was 133 to 137 
(133 to 137 mEq/L) in six patients, 128 to 132 mmol/L [128 to 132 mEq/L] in nine, and 
123 to 127 mmol/L [123 to 127 mEq/L] in three. It returned to normal during therapy in all 
patients. 
The initial treatment in the hospital reduced body weight by 3 to 22 kg (mean, 11.0 ± 
5.2 kg) and improved the New York Heart Association classification in all patients, with 18 
patients changing from class IV to III, 14 from class Г to Π, and three from class III to II 
(Table II). 
The rate of edema reduction was readily adjustable and ranged from 3 to 10 kg/d (Fig 
1). The fast dehydration accomplished with high-dose furosemide in the edematous state of 
chronic congestive heart failure was well tolerated, and the amount of fluid removed daily 
equaled that of the amount that can be removed by daily hemofiltration sessions. When 
normal hydration was attained or dehydration with reduction of the effective circulating 
volume occurred, the furosemide dose was reduced and only oral administration was used 
until discharge. Fast dehydration achieved in this way proved safe even in aged patients 
and resulted in the rapid relief of dyspnea and coughing, a reduced risk of pneumonia, and 
an early discharge from the hospital. 
The maximum oral dose prescribed at the outpatient clinic for at least four weeks was 
250 to 2500 mg (mean; 960 ± 688 mg [n=31]). In most cases, the dose required to control 
recurrent edema had to be gradually increased during follow-up, probably because of the 
progressive decrease in left ventricular function. 
The mean survival time from the day of the first high dose of furosemide was 11.3 ± 
8.9 months for the entire group (range; 0.5 to 36 months) and 12.0 ± 9.4 months when 
survival in the eight patients undergoing hemofiltration was added (Fig. 2). The wide range 
of survival time reflects the heterogenity of the patient population. Four patients survived 
half a month or one month and two patients two months; 14 survived more than a year and 
four more than two years. All but four patients were discharged from the hospital and 
returned to their homes or nursing homes. 
Twenty-five patients died during the period of observation, most of them of 
increasingly severe chronic congestive heart failure (n=13 [Table II]). Other causes of death 
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Figure 2. Kaplan-Meier survival curves for patients who underwent furosemide therapy 
only (broken line) and for those who also underwent long-term intermittent hemofiltration 
(solid line). Numbers along curves indicate numbers of patients. 
were myocardial infarction, pneumonia, ileus, gastrointestinal hemorrhage, cerebrovascular 
accident, and bleeding aortic aneurysm. 
When resistance to high-dose furosemide developed, long-term intermittent 
hemofiltration was perfonned in eight relatively young, alert patients, and furosemide was 
no longer prescribed. In one man, hemofiltration session was performed once per four- to 
six-week period for rapid weight reduction because his weight was slowly increasing 
despite maximal conservative treatment (Fig. 3). In the other 7 patients, the vigorous 
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Figure 3. Results of hemofiltration (HF) in a 54-year-old man (pat 8) with severe chronic 
congestive heart failure refractory to treatment with furosemide (1500 mgld). Daily urine 
volume (UV) and urinary sodium (US) excretion were insufficient to reduce body weight 
(BW). Two hemofiltration sessions reduced body weight by about 10 kg in two days. In 
the outpatient clinic, three more hemofiltration sessions were required to reduce body 
weight, which was slowly increasing despite increasing furosemide dosages. Endogenous 
creatinine clearance (ECC), serum urea nitrogen (SUN), and serum creatinine (SCr) 
values remained reasonably stable. 
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dehydration during hemofiltration greatly reduced renal function (endogenous creatinine 
clearance; 0.05 to 0.17 mL/s/1.73 m2 [3 to 10 mL/min/1.73 m2]), necessitating twice-
weekly renal replacement therapy. These patients had end-stage renal failure and were in 
fact undergoing dialysis. Six of them died during the study and the survival time with long-
term intermittent hemofiltration was 1, 2, 4 and 4 weeks and 5.5 and 7.5 months, 
respectively (Table II). Two patients are still undergoing hemofiltration (after five and 3.5 
months). 
Hypokaliemia was an important, almost constant side effect of high-dose furosemide 
therapy; 31 patients needed potassium-sparing diuretics and/or potassium chloride 
supplementation to maintain a normal serum potassium level. Serum uric acid levels were 
elevated during therapy in all patients (Table II), with a mean of 620 ± 120 \imoi/L (10.4 ± 
2.0 mg/dL) (range; 340 to 820 \imo\/L [5.7 to 13.8 mg/dL]; normal <420 цтоІ/Ь [<7.1 
mg/dL] for men <340 цто1/Ь [5.7 mg/dL] for women). Attacks of gouty arthritis 
necessitated uricosuric therapy in four cases. Dehydration requiring hospitalization and 
rehydration with reduction of the furosemide dosage occurred in two outpatients, who 
suffered no further ill effects. Tinnitus or hearing loss was not observed. 
Comment 
The use of high-dose furosemide in the treatment of refractory chronic congestive heart 
failure has attracted relatively little attention [8]. The number of patients with congestive 
hean failure who have significantly reduced renal function may have been underestimated. 
The mean creatinine clearance in our patients in their best circulatory state was 0.53 
mL/s/1.73 m2 (32 niIVmin/1.73 m2). Moreover, these patients are usually elderly and have 
a decreased muscle mass, especially when exercise is hampered by diminished cardiac 
function. In such cases, even a normal and certainly an (even slightly) increased serum 
creatinine concentration may indicate significantly reduced renal function, which is 
discovered only if the creatinine clearance is calculated [9]. The decreased renal function is 
probably due to a combination of prerenal factors (low cardiac output and blood pressure) 
and renal factors (arteriosclerosis and arteriolosclerosis). 
The site of action of furosemide is the thick segment of the medullary and cortical 
ascending limbs of Henle's loop, where, acting from the tubular lumen, the drug inhibits 
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the coupled transport of sodium and chloride from the lumen into the cell. Furosemide is an 
organic acid firmly bound to serum protein; it therefore reaches the tubular lumen 
predominantly by active secretion from blood into the urine via the organic acid transport 
system of the straight segment of the proximal tubule, and not by glomerular filtration [2]. 
In renal insufficiency, furosemide secretion is partly reduced by decreased renal blood 
flow, but the major limitation of its access into the urine seems to be diminished secretion 
resulting from blocked transport, which is due to an accumulation of endogenous organic 
acids [10]. Natriuresis can be effected by forcing sufficient amounts of furosemide into the 
urine. High doses result in a high concentration of furosemide molecules, which can better 
compete with the endogenous organic acids for the receptor sites of the active secretory 
tubular transport system. 
Furosemide has significant renal and extrarenal hemodynamic effects in congestive 
heart failure [11]. The earliest and frequently clinically important hemodynamic changes 
reflect vascular rather than diuretic mechanisms. There is a rise in venous capacitance and a 
fall in vascular resistance, which reduce preload [11]. Furthermore, renal plasma flow is 
increased within 15 minutes [11]. These vascular effects probably play a role in 
furosemide's mode of action, independently of the strong diuretic mechanisms. 
Resistance to conventional furosemide doses in patients with chronic congestive heart 
failure seems to be caused not only by impaired renal function but also by decreased 
absorption from the gut [10,12]. Absorption is delayed because of slow gastric emptying, 
edema, and changed intestinal motility and perfusion. The mode of administration is 
therefore important; intravenous injection is most effective, as it circumvents the altered 
absoption of furosemide in heart failure [10]. However, there may be no response even 
when furosemide is given intravenously in boluses of up to 250 mg. Slow, continuous 
intravenous pump infusion seems the most effective and least toxic mode of administration. 
Our results in this heterogenous group of patients show that high-dose furosemide can 
be useful in the treatment of gross edema refractory to all other medications, including 
Captopril and vasodilators. It results in the rapid removal of excess water and salt, which 
can be managed safely even in the normal ward. Given careful monitoring of the hydration 
state and effective circulating volume, outpatients can also be safely treated with high-dose 
furosemide (up to 2.5 g/d). 
At the start of high-dose furosemide therapy, almost half our patients showed 
hyponatremia. Its presence seemed to depend not only on the severity of heart failure but 
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also on previous therapy. In some cases, hyponatremia might be caused by a previous in-
hospital regimen of strict salt restriction and moderate diuretic doses [2]; in others, a normal 
serum sodium level could be the result of only slight salt reduction and moderate doses of 
furosemide. Furosemide can be used in treating hyponatremic, edematous patients because 
its medullary action inhibits both the diluting and the concentrating ability. The passage of 
relatively isosmotic urine will not further lower the serum sodium level [2]. Hyponatremia 
was not a contraindication to high-dose furosemide therapy when no strict salt reduction 
was prescribed, and indeed the serum sodium level returned to normal in all our patients. 
None of our patients complained of hearing loss or tinnitus during therapy. Although 
no serial audiometrie studies were perforaied, it seems safe to say that ototoxic side effects 
did not occur. 
The use of high-dose furosemide seems to serve a dual purpose. First, it can quickly 
reduce gross edema (within a few days), to reduce the hospital stay of patients who are not 
at the end of all therapeutic possibilities; after the edema disappears, other therapeutic 
combinations can be tried with lower doses of furosemide. Second, high-dose furosemide 
can be used when more conventional treatments have failed, as in this study; it should be 
tried when salt restriction and low to moderate doses of diuretics, digitalis, vasodilators, 
and Captopril fail to control the edema. 
In spite of the absence of a matched control group, we think that high-dose furosemide 
almost certainly prolonged the life span of our patients by postponing circulatory and 
respiratory failure. It enhanced the quality of life by reducing coughing and dyspnea. High 
doses of furosemide are effective and can be given even over a long period (up to three 
years) without serious side effects. However, it is merely symptomatic therapy, and the 
quality and performance of the left ventricle ultimately seem to determine patient survival. 
Long-term intermittent hemofiltration was used as a final resort, with varying success. It 
may nevertheless be tried in selected patients and in some may lead to a not insignificant 
prolongation of life, mostly by sacrificing renal function for cardiac performance. 
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in reply.- The data in our study clearly support the point of view of Dr Rottellar and his 
colleagues that a maximum orally administered dose of 600 mg/d of furosemide can be 
exceeded safely [1]. Orally administered doses up to 2000 to 2500 mg/d were tolerated well 
by patients with chronic congestive heart failure, and major side effects did not occur when 
the drug was administered by those with experience, especially when hypokaliemia and 
volume status was monitored and corrected carefully. Continuous intravenous infusion in 
these patients was, in our experience, safe up to a dosage of 2000 mg/d, and serum 
furosemide levels did not exceed 120 mol/L. Intravenous bolus injection, of course, yields 
the highest serum furosemide levels and risk of ototoxicity [2]. Thus, for this mode of 
administration, a maximum of 1000 mg/d of furosemide with an infusion time of 30 
minutes can be recommended [3]. The use of high doses of furosemide in patients with 
severe renal insufficiency has attracted more attention [3, 5]. Preliminary data from our 
group also show that even in patients undergoing hemodialysis (but with some residual 
function) resulting in diuresis (>100 mL/d), orally administered furosemide (up to 2000 
mg/d) can be given safely. In these patients, serum furosemide levels did not exceed 121 
mol/L and ototoxicity, as measured by repeated audiometry, did not occur. In conclusion, 
we agree with the call by Rottellar et al for réévaluation of the maximum recommended 
orally administered dose of furosemide in patients with renal failure and/or congestive heart 
failure in the United States. 
P.G.G. Gerlag, MD, J.J.M. van Meyel, MD, R.W. van Olden, MD, St Joseph Hospital, 
P.O. Box 259, 5600 ML Eindhoven. 
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Summary 
The effects of daily administration of 250 - 2000 mg furosemide (F) were studied in 
patients on hemodialysis who still had residual diuresis. In a short study 10 patients 
(endogenous creatinine clearance 0.6 - 5.3 mllminll.73 m2) were treated with 1000 mg of 
F twice daily during 7 days and in a long term study 13 patients (endogenous creatinine 
clearance 0.7-6.8 mllminll.73 m2) were treated during one year with 250 -1000 mg of F 
orally each day. In the short study we observed an increase of24h volume excretion with 
a median of 109% (p < 0.005). Mean daily urinary sodium excretion increased 210%, 
chloride 346% and potassium 65% when compared with the control period. In the long 
term study a marked initial rise in diuresis and electrolyte excretion was found. However 
during one year follow-up a gradual decrease in response with time was found caused by 
progression of renal disease. There were no signs of ototoxicity. Side effects were bullous 
dermatosis on the limbs after exposure to sunlight in the summer (2 patients). 
We conclude that high dose furosemide is effective in patients on hemodialysis with 
residual urinary production. However on long term the diuretic effects diminish because of 
progression of the underlying renal disease. 
Introduction 
Fluid restriction is one of the cornerstones of dietary treatment in patients with end 
stage renal failure on chronic intermittent hemodialysis. Important interdialytic weight gain 
with development of hypertension and sometimes edema and dyspnea can occur when 
patients do not adhere to their fluid restrictions. Then, vigorous ultrafiltration during 
dialysis is necessary, often with hypotensive episodes and muscle cramps as a 
consequence. Furosemide is a well-known and very effective loop diuretic that can be used 
in high doses in patients with renal insufficiency [1]. A number of pharmacokinetic studies 
have been done in patients with end stage renal failure [2-8]. Two pharmacodynamic 
studies in which patients used daily oral doses of 240 - 500 mg furosemide have been 
published. However in these studies no furosemide concentrations in serum or urine were 
measured [9-10]. 
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The aim of the present study was to investigate the short term and long term 
phaimacodynamic effects of high dose furosemide in patients on chronic hemodialysis with 
residual renal function. At first, a short term and a dose response study were done to 
evaluate the acute effects of high dose (1000 mg and 2000 mg) furosemide in chronic 
hemodialysis patients. Thereafter we studied prospectively during one year the 
phaimacodynamic effects and the influence of high dose furosemide on blood chemistry. 
Patients and methods 
Short term and dose response study. 
Ten hemodialysis patients (4 females) with a urine production of at least 100 ml/day 
were studied. Primary renal diseases were tubulo-interstitial nephritis (4), 
glomerulonephritis (2), athero-sclerotic disease (2), polycystic disease (1) and lupus 
nephritis (1). Patients were selected who were able to carry out careful and accurate urine 
collection. After approval of the protocol by the local hospital committee of medical ethics, 
informed consent was obtained from all patients before participation. Their mean age was 
64 years (range 49-79 years). Participants were in a stable condition with a median time of 
30 months on haemodialysis (range 5-103 mth). They were on hemodialysis two (5) or 
three times a week. The study period was two weeks. Urine of 24 hrs (08.00 - 08.00h) 
was collected each day during 14 days in opaque containers. The first week was a control 
period, during the second week 1000 mg of furosemide (Lasix Forte® Hoechst 500 mg) 
twice daily was administered orally: 1000 mg in the morning 1 to 1.5 hour before the start 
of hemodialysis and 1000 mg around 18.00h. Participants were instructed about the 
possibility of dehydration and its signs and symptoms and were asked to report every side 
effect immediately . The patients were instructed to keep a diet containing 60 mmol sodium 
and 40 mmol potassium. Additional medication, but no other diuretics, was permitted and 
not changed during the study days. Mostly their medication consisted of 
aluminiumhydroxyde, 1-25 dihydroxy-cholecalciferol and antihypertensive drugs. 
Bodyweight and bloodpressure at the start and the end of each dialysis of 3-5 h duration, in 
the supine and upright position were recorded. Plasma sodium, potassium, chloride, urea, 
creatinine, uric acid, calcium and furosemide levels were measured before dialysis and 
urea, creatinine and furosemide also after dialysis. Urine volume, sodium, chloride, 
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potassium, urea, creatinine and protein were measured in daily 24h collections. Urinary 
furosemide concentrations were measured in the last 24h collection of each dialysis-free 
interval. Furosemide concentrations were measured in serum and urine with an HPLC 
method [12]. The other solutes were measured by autoanalyzer. Residual renal function 
was determined by the endogenous creatinine clearance (E.C.C.). This in tum was 
calculated using the mean urinary creatinine from the 24h collections during the complete 
dialysis-free interval and the mean plasma creatinine of the values at the end and the 
beginning of the dialysis on each side of the urine collection period [13]. Audiometry was 
performed twice in the control week and twice in the experimental week by means of an 
audiometer (125-8000 Hz, Peekel). 
After a wash-out period of at least 2 weeks 5 patients, who participated in the short 
study, were studied again. After a new control period of one week they were treated with 
500 mg of furosemide orally twice daily, in the morning 1 to 1.5 hour before dialysis and 
again at 18.00h. Otherwise, the experimental protocol was identical with that of the short 
term study. 
Long term study 
Thirteen patients on hemodialysis (4 females) with varying causes of end stage renal 
disease (tubulo-interstitial nephritis 4, glomerulonephritis 2, atherosclerotic disease 4, 
lupus nephritis 1, unknown 2) agreed to participate in a long term study during one year. 
Their mean age was 66 years (range 50-77 y). They were on chronic hemodialysis for a 
median of 15 months (range 4-88 mth). Their condition was stable. Dependent on their 
diuretic response in a period of dose finding, they were treated with a fixed dose of 
furosemide of 250-1000 mg daily. Three patients received 250 mg, another three 500 mg, 
one 750 mg and six 1000 mg furosemide a day. Furosemide 250 mg was given in the 
morning, 1 to 1.5 h before dialysis. Higher doses were divided in two equal doses and 
administered in the morning and at 18.00h. At the start and the end of each dialysis 
bodyweight and bloodpressure in the supine and upright position were recorded. Plasma 
sodium, potassium, chloride, urea, creatinine, protein, uric acid, calcium, osmolality and 
furosemide levels were measured at monthly intervals during the first 3 months and three-
monthly in the next period. The urine values presented in tables I, II and ΠΙ are the mean of 
24h collections during the longest dialysis-free interval before each experimental plasma 
sample. Twice weekly the patients were asked for complaints, using a standard specially 
57 
designed questionaire. Audiometrie control was performed as control and every three 
months during the study. 
Statistics 
The non-parametric two sided test of Wilcoxon and the Spearmans test are used for the 
urine parameters in the short term and long term study because the data in this population 
are not normally distributed. Differences between the plasma parameters were tested with 
Student's t-test. Plasma values are given as mean values ± standard error of the mean 
(SEM). 
Results 
Short study 
The 10 patients in this study had a mean E.C.C, of 1.9 ml/min/1.73 m2 (range 0.6 -
5.3). Figure 1 presents the daily urine volume excretion of one representative patient (nr 4), 
during the complete study period. Table I shows the mean daily urine volume excretions in 
HD HD HD HD 
Time (days) 
Figure 1. Short term study: daily urine volume excretions of one patient during a control 
period and during therapy with 1000 mgfurosemide twice daily. HD = hemodialysis. 
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Table l. Short study: renal function, furosemide (F) levels, and mean diuresis during the 
control-period (С) and during exposure (E) to furosemide (2000mg/d). 
Patient 
1* 
2* 
3 
4 
5 
6 
7 
8 
9 
10 
ECC 
nil/min/1.73in2 
5.3 
5.2 
3.6 
2.8 
1.9 
1.8 
1.7 
0.9 
0.6 
0.6 
Diuresis 
ml/day 
С 
930 
1160 
1110 
740 
240 
190 
440 
230 
210 
100 
E 
1620 
1880 
1680 
1540 
810 
600 
1210 
470 
400 
210 
Serum F 
ЦЕ/ШІ 
16.4 
11.2 
29.5 
25.1 
35.8 
28 
25.7 
30.8 
13.8 
57.1 
Urine F 
mg/day 
13 
19 
18 
20 
16 
39 
10 
4 
4 
6 
Median 1.9 340 1010 26.4 14.5 
'dose F had to be reduced from 2000 to 500 mg/d 
+p < 0.005 
Table II. Short study: daily urinary excretion and serum parameters in the control-period 
(C) and during exposure (E) to furosemide. 
Urinary excretion 
Median Range 
Plasma concentration 
Mean SEM 
Na (mmol) 
Cl" (mmol) 
К (mmol) 
Urea (mmol) 
Protein (g) 
С 
E 
С 
E 
С 
E 
С 
E 
С 
E 
20 
100* 
17 
103* 
И 
23* 
30 
45+ 
0.8 
0.9 
7-87 
25-169 
5-52 
25-150 
1-35 
3-50 
5-97 
6-113 
0.1-4.8 
0.2-М 
143 
139* 
104 
99* 
5.0 
4.4* 
1.7 
1.6 
1.9 
1.9 
0.09 
0.09 
*р < 0.005, + р< 0.01 
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the control and experimental week. All patients experienced more diuresis during 
furosemide treatment. Even in patients with a very low basal urine volume (100 or 200 
ml/day) a definite effect was found. Because of signs of dehydration in both patients with 
the highest E.C.C. (5.3 and 5.2 ml/min/1.73 m2) the dose of furosemide had to be reduced 
to 500 mg after 2 and 3 days. During the study week there was a significant increase of 
urinary volume (109%), and of sodium (210%), chloride (346%), potassium (65%) and 
urea (29%) excretions (table II). Urinary furosemide excretion ranged 4 to 39 mg/day 
(median 14.5 mg/day, table I). The mean increase of urinary volume and the excreted 
amount of furosemide correlated positively with the residual creatinine clearance (p<0.05, 
Spearmans test). Protein excretion did not increase and no relation was found between 
urinary protein and furosemide excretion. The mean body weight gain during the 
interdialytic interval was 1.0 ± 0.2 kg less than between the two intervals before treatment 
with furosemide (p<0.005). This resulted in an important reduction of blood pressure in 
some patients, but mean blood pressure before dialysis did not change significantly. 
Predialysis plasma concentrations of furosemide at the start of the last dialysis of the 
treatment period were below 100 μg/ml in all patients. Predialysis furosemide levels were 
taken 1 to 1.5 hours after administration of the medication and did not represent the exact 
peak serum concentration. However, in all patients postdialysis furosemide levels were 
lower than predialysis concentrations. Mean plasma albumin concentration was 31 g/1 
(SEM 0.9 g/1). No correlation was found between the individual plasma concentrations of 
albumin and furosemide. Mean predialysis plasma concentrations of sodium, chloride and 
potassium were somewhat lower during furosemide medication, but the differences were 
clinically not relevant (table II). Repeated audiometry showed no changes. The two patients 
with the highest E.C.C., suffered from dehydration. This could be corrected by extra oral 
fluid intake and decreasing of the furosemide dose. These two patients complained 
temporarily about tinnitus during dehydration, 3 other patients reported nausea and 1 
diarrhoea. All patients, but one, wanted to continue with furosemide. 
Dose response 
The effects of 500 and 1000 mg furosemide twice daily on urinary volume and sodium 
excretion are shown in figure 2. The highest dose produced the highest increase (p<0.05) 
The potassium excretion remains equal. 
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VOLUME EXCRETION (ml/24h) 
2000 
1000 
I Control 
I Furosemide 2 χ 500 mg 
• Control 
0 Furosemide 2 χ 1000 mg 
t HD t
6 
HD D 
Days 
SODIUM EXCRETION (mmol/24h) 
200 -
100 
Figure 2. Dose response study: mean urinary volume and sodium excretions in 5 patients 
during the control periods of 7 days and after daily administration of 1000 mg and 
2000mg offurosemide during 7 days. HD = hemodialysis 
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Table Ш. Longterm study (n=10): urine parameters and renal function of the pretreatment 
period and during 12 months with a fixed dose furosemide (250-1000 mg); median 
compared with pretreatment levels, furosemide excretion compared with the excretion after 
3 months. 
Months Median Range 
Volume 
(mVday) 
Na+ 
(mmol/day) 
ci-
(mmol/day) 
K+ 
(mmol/day) 
Ca2+ 
(mmol/day) 
Osmol 
(mosmol/kg) 
Furosemide 
(mg/day) 
ECC 
(ml/min/1.73m2) 
0 
3 
6 
9 
12 
0 
3 
6 
9 
12 
0 
3 
6 
9 
12 
0 
3 
6 
9 
12 
0 
3 
6 
9 
12 
0 
3 
6 
9 
12 
3 
6 
9 
12 
0 
3 
6 
9 
12 
750 
1250* 
960* 
625 
710 
37 
75* 
54* 
40 
41 
14 
69* 
52* 
40** 
42** 
21 
28* 
27** 
16 
28** 
0.40 
1.04** 
1.05** 
0.62 
0.69 
296 
287 
275 
284 
280 
11.9 
8.9** 
7.9* 
7.5* 
5.6 
4.5** 
4.3** 
3.2** 
1.9** 
120 -
200 -
180 -
140 -
180 -
6 -
16 -
12 -
9 -
9 -
2 -
16 -
12 -
9 -
10 -
1 -
2 -
3 -
2 -
9 -
0.12 -
0.35 -
0.26-
0.21 -
0.19-
212 -
223 -
207 -
182 -
229 -
2.1 -
1.9 -
1.4 -
1.1 -
0.7 -
0.6 -
0.6 -
0.5 -
0.5 -
1290 
1840 
1580 
1580 
1820 
68 
115 
142 
155 
153 
49 
103 
118 
135 
144 
45 
55 
49 
56 
50 
1.35 
2.30 
2.35 
2.18 
2.19 
455 
323 
328 
332 
359 
33.4 
26.8 
26.6 
27.2 
6.8 
6.4 
6.3 
6.0 
5.9 
ρ < 0.005. ρ < 0.02 
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Long-term study 
In 10 of the 13 patients a one year follow-up was completed. Furosemide treatment was 
diminished in 3 patients: one because of kidney transplantation after 6 months, one because 
of a cerebrovascular accident after 10 months and one patient discontinued furosemide after 
7 months because of bullous dermatosis. The effects on urinary volume, electrolyt and 
furosemide excretions, osmolality and E.C.C. are shown in table Ш. An initial rise in urine 
production of 58% after 3 months was followed by a gradual reduction. After one year the 
pretreatment level was reached again. Also urinary excretion of sodium, potassium, 
chloride and calcium were increased at 3 months but diminished thereafter. The E.C.C, and 
the furosemide excretion decreased in time. Urinary protein concentration (median; 0.9 gfl, 
range 0.1-2.3) showed no change in time. Plasma levels of sodium, chloride, potassium, 
calcium, uric acid, magnesium and osmolality showed no significant changes. All 
furosemide plasma concentrations were below 40 μg/ml. Three monthly audiometry did not 
show ototoxicity and no significant changes were found. Two patients developed bullae of 
the skin of their limbs after exposition to sunlight in the summer. These bullae disappeared 
spontaneously after avoidance of sunlight while furosemide administration was continued. 
Discussion 
In the present short study we showed that 2000 mg furosemide given to hemodialysis 
patients with an E.C.C., that ranged from 0.6 to 5.3 ml/min/1.73m2, gives a doubling of 
the residual urinary production. In a study in 8 patients on regular dialysis, Schmidt et al. 
compared the diuretic effects of 240 mg furosemide and 240 mg muzolimine on the second 
day of the interdialytic interval of three days with the pre- and posttreatment day [9]. 
Vereerstraeten et al. in a study in 9 chronic dialysis patients, compared the diuretic effects 
of 500 mg furosemide with a placebo administered during 14 days [10]. Urine was 
collected twice a week during the 24 hours preceding each hemodialysis. The increase of 
urinary volume and sodium excretion was limited in both studies, but there was a 
significant response of the remaining nephrons to these loop diuretics. We used a higher 
dose of oral furosemide compared with earlier pharmacodynamic studies [9,10]. This 
resulted in a more pronounced increase of diuresis, and excretions of sodium and chloride 
than when 240 mg or 500 mg furosemide orally were used [9,10]. These results were 
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reached despite half our patients had a mean diurnal control urine volume less than 300 ml, 
while the patients in the two other studies had a diuresis of more than 300 ml/day f9,10]. 
In a recent study, it has been presumed that the remaining nephrons respond at least 
normally and may demonstrate an exaggerated response to amounts of diuretic reaching 
them [11]. In a study in 8 patients with a creatinine clearance range from S to 18 
ml/imn/1.73m2, but not on chronic hemodialysis, Brater et al. demonstrated that a single 
intravenous dose of 160 mg of furosemide is sufficient to reach the upper plateau of the 
dose-response curve in each patient [11]. The results of our study clearly show that the 
remaining nephrons in end stage chronic renal disease keep their sensitivity to the loop 
diuretic furosemide, even when they are very small in number. This is in agreement with 
the results of studies investigating the effects of furosemide in acute oliguric renal failure 
[14,15]. Furosemide plasma concentrations were below the estimated ototoxic level of 100 
μg/ml in all participants. The two patients with an E.C.C, greater than 5 ml/min/1.73m2 
could not compensate for the large diuresis on 2000 mg furosemide by increasing the fluid 
intake. In addition, the decrease of plasma sodium, chloride and potassium in the short 
study was also mainly caused by the patients with the highest creatinine clearances. 
Because of these observations, individualization of the daily amount of furosemide in these 
patients is necessary and because of the shown dose-response relationship lower doses 
(250-1000 mg) can be chosen on the basis of E.C.C, and residual diuresis. However, 
1000 mg furosemide twice daily seems the maximal oral dose that can be given safely to 
patients on dialysis with a residual diuresis of more than 100 ml/day. 
In the long term study increases of diuresis and excreted electrolytes were reached. 
Plasma concentrations of furosemide never exceeded 100 μg/ml. Derangements of plasma 
electrolytes did not occur and so long term use proved to be safe. As expected, there was 
an increase of calcium excretion but it seemed too low to reach clinical significance. 
The decrease in time of the efficacy of the fixed dose of furosemide seems fully 
explained by the measured decrease of renal function caused by progression of the 
underlying renal disease. Theoretically, the dose of furosemide can be increased above 
1000 mg a day during the follow up period to maintain a maximal diuretic effect. However, 
no information is available about the efficacy and the toxic potential of long term treatment 
with a furosemide dose higher than 1000 mg a day. 
Ototoxicity is a major side-effect of treatment with high dose furosemide [16]. 
However, the audiometrie controls in the acute and chronic study showed no signs of 
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ototoxic damage in the important normal hearing range. It needs to be stated that an 
ordinary audiometer was used (125-8000 Hz). The early damage of ototoxic drugs is 
reported to occur in range of high frequencies (10.000-20.0000 Hz) but high frequency 
audiometry was not available to us [17]. 
The development of sunlight induced bullae on limbs and face are an important 
complication. In a study in 56 chronic hemodialysis patients, all treated with daily 
furosemide doses of 500-2000 mg, 12 patients (21%) developed bullae in areas exposed to 
sunlight [18]. The clinical and histological picture is identical with that of porphyria cutanea 
tarda and of bullous dermatosis of haemodialysis [19]. The diagnosis is based on a positive 
history of drug ingestion and resolution of the lesion after discontinuation of furosemide. A 
photosensitizing mechanism of furosemide or its metabolites seems to be involved. 
Prevention of this complication requires avoidance of sunlight exposure. When doing so, it 
is not necessary to stop furosemide medication. 
Summarizing our results, it is obvious that high dose furosemide orally (up to 1000 mg 
twice daily) is effective in chronic haemodialysis patients. The daily diuresis of the patient 
can be doubled. However, because of the limited effect on the long run and the presence of 
side effects the use of high dose furosemide in hemodialysis should be restricted to those 
patients who tend to important interdialytic overhydration despite residual diuresis. 
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Summary 
Furosemide delivery rate in the nephron has been reported to be one of the major 
determinants of diuretic response. In a randomized, crossover double-blind study in eight 
healthy volunteers we tested this hypothesis by comparing continuous intravenous 
infusion of furosemide (infusion rate 4 mglhr) during 8 hours after administration of an 
intravenous loading dose of 8 mg (total dose 40 mg) with an intravenous bolus injection of 
40 mg of furosemide. During the study days subjects were rehydrated with isovolumetric 
amounts of fluid. Mean total urinary volume (V^), sodium (UNa), potassium and chloride 
excretion after 8 and 24 hours were significantly greater after treatment with continuous 
furosemide infusion when compared with bolus injection, whereas total urinary 
furosemide excretion showed no differences (Vurbolus vs UVurinfusion; 5270 vs 6770 
ml/8 hours, UNabolus vs UNainfusion; 314 vs 430 mmollS hours, both p<0.001). These 
findings strongly support the concept of the furosemide delivery rate into the nephron as a 
determinant of diuretic efficiency. 
Introduction 
Furosemide is a high-ceiling diuretic agent often used in clinical practice to treat 
edematous states in congestive heart failure, nephrotic syndrome and liver cirrhosis. 
After secretion into the proximal renal tubule, furosemide exerts its effects from the 
luminal side of the thick ascending limb of the loop of Henle, where it inhibits reabsorption 
of chloride and secondarily of sodium. Recent studies show a correlation between the 
urinary excretion rate of furosemide and its diuretic efficiency.1"4 In addition, Kaojarem et 
al. ' stated that the time course of delivery of furosemide is one of the overall determinants 
of diuretic effect. According to this concept a low but continuously effective urinary 
excretion rate of furosemide would lead to a higher diuretic effect than short exposure of 
the active site to high concentration of the drug as occurs with bolus administration. 
Consequently, continuous infusion of furosemide may be the most efficient way of 
administration of this kind of drug. Up to now, few studies have been performed that 
address this issue. In an animal study Lee et al.2 compared different lengths of infusion 
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time using the same total dose of furosemide. They found increasing diuretic effects with 
increasing infusion times, whereas the pharmacokinetic parameters were not significantly 
different between the four infusion times. In an uncontrolled study Lawson et al.5 showed 
the usefulness of continuous furosemide infusion in patients with refractory congestive 
heart failure. However, Copeland et al.6 did not find pharmacodynamic differences 
comparing continuous infusion versus bolus injection in a study in 18 post-operative 
patients. Yet, it must be stressed that these two studies were open, not blinded nor 
randomized in a cross-over design. 
The aim of the present study was to compare the pharmacodynamic effects of a bolus 
injection of furosemide with an equivalent dose administered as a continuous infusion in 
healthy volunteers in a randomized, crossover, double-blind fashion. 
Methods 
Subjects. After approval by the local hospital ethical committee, we selected eight 
nonsmoking male volunteers for the study. From each subject a written informed consent 
was obtained before participation. Age range of the subjects was from 21 to 41 years and 
weight range from 67.5 to 75.5 kg (Quetelet index; mean ± SD; 22.5 ±1.2 kg/m2, range 
20.2-23.8). Each subject had a normal medical history, physical examination, complete 
blood count and biochemistry. None of the subjects used any medication before study 
entry. 
Study design. The study was designed as a double-blind randomized crossover study, 
in which all subjects participated in two study days. The diet three days before (day 1 to 3) 
and on each treatment day contained 150 mmol sodium and 80 mmol potassium. 
Volunteers were not allowed to drink coffee, tea or alcohol throughout the treatment days. 
Urine was collected for 24 hours on the day before the study day to assess adherence to the 
diet. The study started in the morning of day 4 at the close of the 24-hour urine collection. 
On the treatment days the volunteers received, after an initial bladder voiding, either a bolus 
injection of 40 mg (4 ml) furosemide intravenously followed by a continuous infusion of 
saline solution at a rate of 4 ml/hr or a loading dose of 8 mg of furosemide (dissolved in 4 
ml saline solution) followed by continuous infusion of furosemide (furosemide 
concentration lmg/ml) at a rate of 4ml/hr for 8 hours. To prevent the photochemical 
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degradation of furosemide both infusions were protected against light. According to the 
formula 
intended infusion rate (mg/hr). t j^ (hr) 
Loading dose = 
0.7 
we calculated that a loading dose of 8 mg intravenously followed by a 4 mg/hr continuous 
infusion was necessary to reach a steady-state plasma furosemide level. With respect to this 
calculation, we assumed a half-life ( t^) of furosemide of 90 minutes. The t ^ after 40 mg 
of intravenous furosemide in healthy volunteers in 11 studies ranged from 45 to 172 
minutes.7 Urine losses of each period were replaced volume for volume by a combination 
of a continuous intravenous saline infusion and tap water orally during the subsequent 
period. Between the 2 treatment days there was a washout period of at least 7 days. At the 
contralateral side of drug infusion, blood samples for the determination of plasma drug 
concentration were drawn by way of an indwelling heparinized catheter in an antecubital 
vein at 0, 15, 30, 45, 60, 90, 120, 150, 180, 240, 300, 360, 420 and 480 minutes after the 
start of furosemide administration. Plasma and urine samples were stored at -20°C and 
were carefully protected from light until analyzed. On the treatment day, urine was collected 
hourly till 8 hours after the start of the test. During this time the volunteers stayed in the 
hospital. After 8 hours the subjects went home, with no restriction on fluid intake and 
collected urine from 8 to 24 hours. 
Analytical methods. Urine was immediately analyzed for sodium, chloride, potassium 
and creatinine concentration. Sodium and potassium were assayed with a flame 
photometer, chloride by a semi-automatic colometric titration method and creatinine by 
means of Jaffe's method. Plasma and urine concentrations of furosemide were determined 
by a rapid and sensitive HPLC assay that has been described previously.8 
Calculations and statistics. All findings are presented as mean values ± SEM unless 
indicated otherwise. We used the sigmoid maximum effect (Emax) model for the dose-
response relationship, using the data obtained after bolus administration. No high urinary 
furosemide concentrations were reached with continuous intravenous infusion; 
consequently, the full extent of the curve could not be defined. However data during 
continuous infusion followed the same dose-response pattern as that after bolus 
administration. The data were fitted to the Emax model by use of the NONLIN computer 
program.9 Because the diuretic effect of furosemide has been shown to be more closely 
related to the urinary excretion rate rather than to the plasma concentration, we used the 
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urinary excretion rate of furosemide, as proposed by Hammarlund et al.7·1 0, 
Emax · ER 
E = H-Eo 
ERJO* + ERS 
in which E is effect, Emax is the maximum drug effect, EQ is basal effect without stimulus, 
ER is the urinary excretion rate of furosemide, ER50 is the urinary excretion rate at half 
maximum effect and s is the slope factor. 
For calculation of the maximally efficient excretion rate (MEER) we used the formula as 
proposed by Kaojarem et al.1: 
MEER = [ER50S(S-1)]1/S 
Statistical comparisons were assessed by use of the Student t test for paired data. The 5% 
level of significance was used in all cases. 
Results 
As shown in Table I the volunteers were in balance with their diet on the pretreatment 
days. Fig. 1 presents the course of the plasma furosemide concentration and of the urinary 
furosemide excretion rate after bolus administration and continuous infusion (starting with 
a loading dose) during 8 hours. As shown in Fig. 1, continuous infusion of furosemide 
induced steady-state values, of both the plasma furosemide concentrations and the urinary 
furosemide excretion rate throughout virtually the whole study period. By contrast, after 
bolus injection a peak value of furosemide urinary excretion rate during the first hour was 
observed, followed by a distinct decrease during the subsequent hours. The total urinary 
recovery of furosemide after 24 hours averaged 76 ± 6% (range 40 to 94%) in the bolus 
group versus 71 ± 2% (range 65 to 87%) in the infusion group. 
As shown in Fig. 2 an almost stable hourly natriuresis occurred during continuous 
infusion of furosemide. Volume and electrolyte excretion were significantly higher during 
furosemide infusion compared with bolus injection, whereas furosemide excretion, as 
mentioned, showed no difference (Table Π). Even after 24 hours, electrolyte and volume 
excretions remained significantly higher in the infusion group although the volunteers were 
allowed to have unrestricted fluid intake during this time. 
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Figure ¡. Furosemide plasma concentrations (mean ±SEM, upper panel) andfurosemide 
excretion rate (mean ±SEM, lower panel) after bolus injecrion and continuous infusion of 
40mgfurosemide, respectively. 
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Table I. Baseline values (Mean ±SEM) of eight healthy volunteers on the pretreatment day. 
DAY 3 
(before bolus) 
DAY 3 
(before infusion) 
CLCR (ml/min) 
V,,, (ml) 
UNa(mmol) 
Ujf (mmol) 
U Q (mmol) 
122 ± 5 
1200 ± 150 
156 ± 13 
78 ±9 
163 ± 17 
123 ±4 
1370 ±240 
154 ± 11 
81 ± 8 
165 ± 11 
Abbreviations: CLÇR, creatinine clearance; Vur, total urinary volume; и ^
а
, urinary excretion 
of sodium; Uj^. urinary excretion of potassium; U Q , urinary excretion of chloride. 
Cumulative urinary sodium excr 
(mmol 
Time (h ) 
Figure 2. Cumulative urinary sodium excretion (mean ±SEM) during 8 hours after bolus 
injection and continuous infusion of 40 mgfurosemide, respectively. 
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Table //. Volume, electrolyte andfurosemide excretion 8 and 24 hours фег administration of 
40 mgfurosemide as a bolus or continuous infusion. 
VurCml) 
UNa(mmol) 
Ujç (mmol) 
U Q (mmol) 
ufurosemide(m8) 
BOU!S 
0-8 h 
459 ± 320 
274 ± 8 
51 ± 3 
297 ±8 
30.2 ± 2.3 
0-24 h 
5270 ±360 
314 ±7 
78 ±3 
329 ± 6 
30.7 ±2.3 
INFUSION 
0-8 h 
5830 ±360 
401 ± 19 
63 ±5 
463 ±21 
28.5 ±0.8 
0-24 h 
6770 ±280 
430 ± 17 
95 ± 6 
479 ± 20 
31.4 ± 1.0 
В YS I 
0-8 h 
[кО.001 
p<0.001 
IKO.05 
IKO.001 
n.s. 
Data are mean values ± SEM. 
Ufurosemide' """эту excretion of furosemide 
SODIUM EXCRETION RATE (цтоі/іліп) 
¿000 
* 1 
3000-
2000 
1000-
1000 I 10 100 1000 
FUROSEMIDE EXCRETION RATE ((igftnin) 
Figure 3. The data of the dose-response curve of two subjects (#1 and US) after bolus 
injection (closed circles) and continuous infusion (open circles) of 40 mg offurosemide 
(curves are representative for all volunteers). 
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Table III. Parameters obtained by fitting the data to the sigmoid Ещщ model and the derived 
efficiency parameters after intravenous bolus injection of 40 mgfurosemide. 
Subjects 
No 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
Mean 
(SD) 
Sodium 
^„ftimol/min) 
2140 
3896 
3546 
3375 
2845 
3667 
2270 
2380 
3010 
(690) 
Furosemide 
ERsoíHg/nun) 
76 
170 
99 
ПО 
91 
131 
77 
90 
105 
(32) 
s 
3.66 
1.73 
2.88 
1.72 
2.63 
2.10 
3.62 
3.31 
2.71 
(0 80) 
Sodium Eg 
(jimol/imn) 
99 
68 
120 
36 
83 
89 
282 
145 
115 
(75) 
Furosemide 
MEERöig/mm) 
99 
142 
123 
91 
ПО 
137 
100 
116 
115 
(18) 
Sodium EMEKR 
№
+(цлю1Лшп) 
1655 
1708 
2436 
1448 
1845 
2013 
1925 
1810 
1860 
(290) 
I* 
0.997 
0.978 
0.989 
0.961 
0.984 
0.985 
0.971 
0.974 
Abbreviations: E
m a x
, maximum obtainable natnuresis; ERJQ, furosemide excretion rate causing half 
maximum natnuresis, s, slope factor, EQ, basal diuresis without diuretic stimulation; 
MEER, maximal efficient excretion rate; E ^ E E R , natnuresis occunng at MEER; r\ correlation coefficient. 
Table ΠΙ shows the parameters obtained by fitting the data to the sigmoid Emax model 
and the derived efficiency parameters. The individual data of the dose-response curves of 
two volunteers expressed as urinary sodium versus furosemide excretion rate are presented 
in Fig 3. These dose-response curves are representative for all volunteers. It is obvious that 
all data collected during the period of continuous infusion of furosemide are on the steep 
part of the dose-response curve, close to the MEER. 
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Discussion 
Our findings clearly show that the time course of furosemide delivery in the proximal 
renal tubule is an important determinant of diuretic response. Yet, one must keep in mind 
that maximal efficiency does not mean maximal effect per stimulus ( maximal efficacy) but 
the most efficient relation between stimulus and drug effect. Maximal efficiency is time 
dependent, seems strongly influenced by the state of dehydration10 and, as stated by 
Hammarlund et al.1 1, limited by the clockwise hysteresis phenomenon. As a consequence 
of this hysteresis, indicating acute tolerance to the diuretic effect, it is difficult to determine 
the maximally efficient urinary excretion rate of furosemide. However, in the current study 
acute tolerance development was prevented by use of isovolumetric fluid replacement 
To calculate the maximally efficient excretion rate, the slope factor seems to play a 
critical role as a determinant of the dose-response curve, as noticed by Kaojarem et al.1 
When using the efficiency formula he calculated that, with a slope factor of 1.23, the most 
efficient furosemide excretion rate was 21.5 μg/min. In our volunteers we measured a 
somewhat higher slope factor (2.7 ± 0.8). Consequently the calculated MEER was higher, 
in fact equaling the ER50. When treated with continuous infusion, urinary furosemide 
excretion rate during steady state in our volunteers was almost twice as high as the 
maximally efficient excretion rate calculated by Kaojarern et al.1 According to our 
calculations, furosemide excretion rate reached maximally efficient values only during the 
first hour of our study. We speculate that total diuresis would have been even higher if we 
had been able to maintain the furosemide excretion rate equal to the MEER. 
In contrast to our study, Copeland et al.6 did not find pharmacodynamic differences in 
a comparison of continuous infusion and bolus injection. However, it must be stressed that 
the study of Copeland et al.6 was not of a crossover design. This could have influenced 
their results, because of the large interindividual differences of furosemide 
pharmacodynamics. In addition, they did not start with a loading dose in the infusion 
treated patients, thereby delaying the beneficial effect of continuous furosemide 
administration. 
It seems likely that the concept of continuous infusion of a loop diuretic, as the most 
efficient maneuver, is applicable to patients with refractory congestive heart failure. 
Especially in these patients higher doses are needed, firstly because most patients with 
severe congestive heart failure have impaired renal function. In addition, neurohumoral 
changes and intrarenal regulatory mechanisms in these patients with severe congestive heart 
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failure may account for possible changes in furosemide excretion into the renal tubule. 
Second, pharmacodynamic changes expressed by the rightward and downward shift of the 
dose response curve contribute to the lower efficiency of furosemide. In practice this means 
that higher doses are needed to have the same effect Use of continuous infusion at a rate 
close to MEER provides an alternative to the use of massive single doses of furosemide. 
Yet, it will remain difficult to predict the MEER in these patients and even in healthy 
volunteers. A comparison of our data with the data of Kaojarern et al.1 shows that there are 
great interindividual differences of the slope factor in healthy volunteers. Consequently, it 
is difficult to assess the correct dose (i.e. the exact individual value) of furosemide with 
maximal efficiency in healthy volunteers, as well as in patients. Moreover, as stated above, 
diuretic efficiency does not take into account the time as a parameter. However, especially 
when high furosemide doses are used in the treatment of patients with refractory congestive 
heart failure, the use of MEER could prevent toxic plasma levels of furosemide. 
Future studies should be done in patients with congestive heart failure and refractory 
edema to compare the diuretic effects of bolus administration with continuous infusion and 
to further explore the potential use of this alternative mode of therapy. 
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Summary 
Continuous intravenous infusion of furosemide has been suggested to be a valuable 
diuretic treatment in the management of patients with congestive heart failure and diuretic 
resistance. In this study 10 patients (age 57-84 years, weight 43.7-88.2 kg) with 
congestive heart failure New York Heart Association (NYHA) class III to IV with an 
assessed amount of edema of more than 5 kg who were refractory to conventional therapy 
were treated with continuous furosemide infusion. 
Treatment was started with intravenous furosemide at a delivery rate of 20 mglh, during 
24h (cumulative dose 480 mg/24h). When, on the next day, there was no response as 
measured by body weight, physical examination and sodium excretion we heightened 
infusion rate gradually up to a maximum dose of 160 mglh (cumulative dose 3840 
mg/24h). During this treatment relief of symptoms and weight loss (Mean ± SD; 12.5 ± 
5kg) was achieved in all patients. The mean (±SD) 24h sodium output rose from 19 ± 16 
mmol (n=10) on oral therapy with 250 mg F to 137 ±85 mmol (n=8) during 80 mglh and 
to 268 ± 124 mmol (n=3) on the maximal dosis of 160 mglh, while mean daily potassium 
output rose from 50 ±21 mmol to 78 ±41 mmol and to 82 ±50 mmol respectively. Mild 
hypokalemia occurred in almost all patients and was succesfully treated by oral potassium 
suppletion. We conclude that continuous infusion of furosemide under careful monitoring 
of the patient is a safe, controllable and efficient treatment in patients with severe 
congestive heart failure and diuretic resistance. 
Introduction 
Despite the important role of ACE-inhibitors, diuretics remain the mainstay in the treatment 
of patients with congestive heart failure (CHF), especially when fluid retention dominates.1 
Conventional diuretic therapy consists of a loop diuretic either as one or multiple oral doses 
or as an intravenous bolus dose.2 Most patients will respond with sufficient natriuresis, 
weight decrease and clinical improvement to this regimen. However, some patients with 
severe CHF show diuretic resistance with an inadequate diuretic response as a 
consequence. Diuretic resistance is a senous life-threatening factor in these patients and 
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seems to represent a final manifestation of congestive heart failure.3 When resistance to 
loop diuretics develops, combination therapy with a diuretic that exerts its action in another 
part of the nephron tubule could be successful.3 However, it must be stressed that severe 
electrolyte disturbances and circulatory collaps has been observed when a combination of 
different diuretics was used. Other therapeutic interventions, especially appropriate for 
patients with severe renal impairement, could be hemofiltration or infusion with positive 
inotropic agents (e.g., dopamin and dobutamin).4·5 Yet, serious side effects limit their use. 
High bolus doses of a loop diuretic are successful6, but may be ototoxic.7 Also continuous 
intravenous infusion of a loop diuretic, to make optimal use of its diuretic properties, has 
been advocated.6·"'11 From a theoretical point of view, continuous infusion of a loop 
diuretic may have two important advantages. Firstly, the diuretic efficiency is optimal when 
there is a constant delivery rate of furosemide to the proximal tubule and secondly plasma 
furosemide levels remain relatively low making ototoxic side effects less likely. Up to now 
there are few data regarding the efficacy of continuous furosemide infusion therapy in 
patients with refractory CHF. Therefore, we conducted a study in patients with severe 
CHF and diuretic resistance investigating the pharmacokinetic and pharmacodynamic 
determinants of response during continuous furosemide infusion. 
Patients and methods 
After approval of the protocol by the local ethical committee, we selected patients with 
severe CHF (NYHA III-IV) of different origin with a proven diuretic resistance and an 
assessed amount of edema of more than 5 kg. Diuretic resistance was defined as a failure to 
lose weight and/or inappropriate urinary sodium excretion (< 50 mmol/24h) despite 
maximal conventional therapy, i.e. bed rest during 2-3 days, salt and water restriction, 
orally and intravenously administered furosemide in a dose of 250 mg a day, digoxin, and 
when possible an ACE-inhibitor. The relevant patient characteristics are shown in table I. 
Their mean age was 71.4 years (range 57 to 84 years) and their mean weight was 72.3 kg 
(range 43.7 to 88.2 kg). The patients underwent a physical examination, complete blood 
count, electrocardiogram, echocardiogram and chest X-ray and all gave their written 
informed consent prior to the study. 
Continuous intravenous furosemide infusion treatment was started by an automatic syringe 
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infusion pump (type STC-521, Terumo Corp., Tokyo, Japan) with 480mg/24h (infusion 
rate; 20 mg/h). Furosemide medication in the infusion pump was protected against light. 
We heightened the furosemide infusion rate gradually when patients did not show weight 
loss or if there was no enhancement of diuresis or natriuresis after 24h. Maximal 
furosemide infusion rate was 160 mg/h (cumulative dose; 3840 mg/24h). 
During their stay in the hospital patients received a diet containing 60-80 mmol sodium and 
80-100 mmol potassium. Total daily fluid intake was limited to 1500 ml. Additional 
medication (e.g., digoxin, Captopril) was permitted and not changed during treatment with 
continuous furosemide infusion. Each day all patients were physically examined by the 
same physician. Continuous infusion was stopped when patients were clinically 
compensated. At that time oral furosemide administration was started with doses of 250 to 
1000 mg a day (500 mg b.i.d.). 
Daily 24h urine collection was carried out and urine was carefully protected from light. 
Aliquots of the urine samples were assayed immediately for sodium, potassium, chloride, 
albumin and creatinine content and the rest of the samples was frozen for later analysis of 
furosemide concentration. Venous blood samples were taken daily for determination of 
electrolytes, BUN, creatinine and plasma furosemide concentration. Also venous blood 
samples were taken on the day of admission and one day before the patients leave the 
hospital, for determination of urate, bicarbonate, albumin, magnesium, aldosterone and 
renin. The concentrations of furosemide in plasma and urine were determined by a recently 
developed HPLC assay, with a solid-phase extraction method.12 Plasma aldosterone and 
plasma renin concentration were determined by radioimmuno assay.13·14 Routine blood 
chemistry was measured by autoanalyser. Diuretic response was expressed as daily sodium 
excretion (ттоІД4Ь) or as fractional sodium excretion (FENa), defined as 
U N a · S e C R 
FEN a (%) 100 
S e N a · UCR 
where U N a is urinary sodium concentration (mmol/l), Se C R is serum creatinine 
concentration (mmol/l), SeN a is serum sodium concentration (mmol/l) and U C R is urinary 
creatinine concentration (mmol/l). Each symbol in the dose-response curve represents the 
mean (SEM) FE N a calculated from 24h urine collections at the day after heightening of the 
furosemide dose and the corresponding furosemide dose. 
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о? Table I. Characteristics of patients with refractory congestive heart failure before and фег the treatment with continuous 
infusion offurosemide. 
Patient 
9 
10 
Mean 
SEM 
Age, Sex 
yn 
64, M 
80,F 
84,M 
68,F 
59. M 
76. M 
82, M 
71. M 
73, F 
57, M 
71.4 
3.0 
Weight 
D 
к 
88.2 
61.3 
43.7 
61.1 
Ш 
81.1 
79.6 
84.3 
618 
78.3 
723 
4.5 
Weight 
decrease 
** 
18.5 
16.6 
6.6 
10.8 
И 
19.1 
7.6 
63 
7.4 
173 
IZO 
1.7 
C L C R 
D 
mìlrnin 
40 
36 
15 
36 
23 
26 
41 
40 
59 
48 
37 
4 
CLcR 
С 
43 
33 
12 
24 
28 
30 
50 
44 
47 
45 
36 
4 
NYHA 
D 
IV 
IV 
IV 
Ш 
IV 
IV 
IV 
IV 
IV 
IV 
с 
I 
Ш 
I 
I 
Ш 
Ш 
Ш 
I 
и 
ш 
Diagnosis 
CAD 
CC 
CAD 
CAD 
PH 
CAD 
CP 
CAD 
CAD 
CAD 
E.F 
% 
15 
18 
20 
35 
17 
15 
19 
28 
17 
26 
21.0 
21 
Other 
medication 
C,D,K.T 
D,K 
D,K 
CD.I.T 
C,D,K,I 
CD.T.Am 
C,D,A 
C,D 
D.K.TTi 
C.D.K 
Max 
F-Dose 
mgl24h 
3840 
3840 
3840 
1920 
2880 
1920 
960 
1920 
480 
2880 
Abbreviations: D = decompensated, С = compensated, C L Ç R = creatinine clearance, NYHA = New York Heart Association, CAD = coronary artery disease, 
CC = congestive cardiomyopathy, PH = pulmonary hypertension, CP = cor pulmonale, EF = ejection fraction, С = Captopril, D = Digoxin, К = K-durette, 
Τ = tolbutamide, I = isosorbidedinitraie. Am = amiodarone, A = acenocoumarol, Th = theophyllin, F = furosemide. 
A two dimensional echocardiography was used to measure left ventricular ejection fraction. 
Patients were daily interviewed for side effects. Values were expressed as mean ± SD 
unless indicated otherwise. 
Results 
The currently investigated patients were resistant to conventional diuretic treatment as 
demonstrated by the very low natriuresis (19 ± 16 mmol/24h, resp. 32 ± 18 mmol/24h) 
despite therapy with 250 mg of furosemide orally resp. intravenously. As shown in table I 
the endogenous Creatinin clearance (E.C.C.) was markedly reduced and the BUN/Creat 
ratio was high in all patients. These parameters including the low ejection fractions (table I) 
give expression to the deteriorated haemodynamic state of these patients. The mean (±SD) 
24-hours sodium output rose from 19 ± 16 mmol (n=10) on oral therapy with 250 mg of 
furosemide to 137 ± 85 mmol (n=8) during 1920 mg/24h and to 268 ± 124 mmol (n=3) on 
the maximal administered dosis of 3840 mg/24h (infusion rate 160 mg/h), while mean daily 
potassium output rose from 50 ± 21 mmol to 78 ± 41 mmol and to 82 + 50 mmol 
respectively. Mean duration of treatment was 13 ± 5 days. Figure 1 shows the daily urinary 
volume and electrolyte excretions and some biochemical parameters of one representative 
patient (#2). Increasing the furosemide dose also increased volume and electrolyte 
excretions. However, when patients were almost in the compensated state, furosemide 
sensibility of the kidney diminished, with a lower natriuresis as a consequence. In all 
patients an improvement of the state of compensation and a weight reduction was realized. 
Mean weight reduction was 12.0 kg (range 6.3 - 19.1 kg). Serum sodium concentrations 
gradually increased to normal values and a mild, easy to treat hypokalemia occurred in 
almost all patients, especially in those patients with hyperaldosteronism. Otherwise no 
serious side effects were observed. 
Table II shows the biochemical parameters before and after continuous furosemide 
infusion when patients were decompensated and again when patients were compensated. A 
small not significant increase in BUN/Creat ratio and a small decrease of mean arterial 
blood pressure (MAP) was observed (MAP ± SEM: decompensated; 82 ± 3.5 mmHg, 
compensated; 78 ± 3.4 mmHg). However, we did not find significant increases in serum 
renin and aldosterone levels. 
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Figure 1. Daily urinary volume and electrolyte excretions during continuous administration 
of furosemide (480-3840 mg/24h) in one representative patient. UNa, urinary sodium 
excretion; UK urinary potassium excretion; C/vo/, urinary volume; Ucreat, urinary creatinine 
excretion; Se
creat, serum creatinine concentration. 
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Table //. Biochemical parameters (Mean ± SEM) of patients with congestive heart failure 
before (decompensated) and фег (compensated) treatment with continuous furosemide 
infusion (n = 10). 
DECOMPENSATED COMPENSATED 
BUN/Creat ratio 
Creatinine clearance, milmin 
Serum sodium, mmolll 
Serum potassium, mmolll 
Serum albumin, gli 
Serum urea, mmolll 
Serum bicarbonate, mmolll 
Serum urate, mmolll 
Serum magnesium, mmolll 
Renin, nmollllhr 
Aldosterone, nmolll 
30.6 
37 
134 
4.3 
31 
16 
30.6 
0.62 
0.88 
15.4 
1.5 
± 
± 
± 
± 
± 
+ 
+ 
± 
± 
± 
± 
3.5 
4 
2.1 
0.2 
2.5 
1.7 
2.4 
0.04 
0.04 
5.4 
0.6 
35.0 
36 
138 
4.1 
32 
18 
32.2 
0.66 
0.98 
15.0 
1.5 
± 4.2 
± 4 
± 0.1 
± 0.2 
± 2.3 
± 2.1 
+ 2.4 
± 0.06 
± 0.06 
± 4.8 
± 0.5 
FRACTIONAL SODIUM EXCRETION (%) 
480 960 1920 2880 
FUROSEMIDE DOSE (mg/24h) 
6-
4-
2 -
0 -
n ^ - ^ ' ^ 
^ ^ 
^ - ^ i 
• 
« 
r ^ ^ - ^ 
> 
3840 
Figure 2. Dose-response relation to continuous administration offurosemide (F) relating 
the F dose (mg) to fractional sodium excretion (%). Each point represents the mean (SEM) 
fractional sodium excretion, calculated from the 24 h urine collections of the patients фег 
heightening of the F dose. 
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Plasma furosemide levels averaged 4.3 ± 2.8 μg/ml (range 2.6 to 5.8 Ug/ml) at the 
lowest infusion rate (20 mg/h) and increased up to 71.1 ± 33.3 ug/ml (range 26.6 to 136.4 
Ug/ml) at the highest infusion rate (160 mg/h). In one patient (#3) furosemide plasma levels 
(119 - 136 ug/ml) were in the ototoxic presumed range (>100 \ig/rru) but even in this 
patient no adverse effects were noticed. This was the patient with the lowest E.C.C, who 
was treated with the maximum furosemide infusion rate (160 mg/h). 
As shown in the dose-reponse relation (Fig. 2) there is a positive correlation (R2 = 
0.958, ρ = 0.0004) between the furosemide dose and fractional sodium excretion, 
indicating that higher furosemide doses induces a greater natriuresis. 
Discussion 
Our study clearly shows that continuous furosemide infusion is an applicable, effective 
and safe treatment in patients with severe CHF and diuretic resistance. Diuretic resistance in 
patients with severe CHF is a multicausal phenomenon and seems to be determined by 
pharmacokinetic as well as pharmacodynamic changes. Firstly, in these patients there is an 
altered absorption that could be surpassed by intravenous administration.15·16 Secondly, 
most patients with severe CHF have an impaired renal function. This causes an 
accumulation of endogenous acid and, as a result of competition, a reduced secretion of 
furosemide from the proximal renal tubule with a decreased diuretic effect as a 
consequence. As shown in our study, this could be overruled by administration of higher 
furosemide doses. Thirdly, in patients with severe CHF there seems to be an increased 
sodium reabsorption from the proximal tubule due to kidney hypoperfusion. In addition, as 
shown in recent studies, diuretic resistance could be a result of the kidney adaptation to 
chronic diuretic therapy, resulting in an increased NaCl reabsorption in nephron segments 
downstream from the site of diuretic action.11 It seems that continuous furosemide infusion 
is a mode of administration that could inhibit this increased sodium reabsorption in the 
distal renal segment. In two recent studies performed in patients with renal failure and in 
healthy volunteers, a higher efficacy of continuous furosemide infusion versus bolus 
administration was demonstrated.17·18 Although we did not compare bolus administration 
with continuous infusion, it is obvious that continuous infusion of furosemide is effective. 
In addition, this treatment modality seems safe, because high and potentially toxic plasma 
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concentrations as seen after bolus administration would be avoided, in addition high 
cumulative dosages could be administrered. Toxic plasma furosemide levels were observed 
in one patient with the lowest E.C.C. (14ml/min) who was treated with the maximum 
furosemide infusion rate (160 mg/h). With respect to toxic furosemide concentrations, a 
daily cumulative dose of 3840 mg (infusion rate 160 mg/h) seems safe when E.C.C, is 
higher than 20 ml/min. As reported in the literature, loss of hearing can occur when 
furosemide infusion rate is higher than 240 mg /h.7 
In all our patients this treatment was successful and well tolerated. As shown in the 
dose-response curve it seems rational to give higher (cumulative) daily doses of furosemide 
than generally advocated. It was not possible to fit the data according to a sigmoid Emax 
model, because maximum values were not reached and consequently the full extent of the 
curve could not be defined.17 An expected finding was that the furosemide sensibility of 
the kidney diminished when patients were almost compensated. As mentioned by Vasco et 
al., this could occur when patients attained dry weight and were in a sodium-avid state.15 
In addition, at that time they were almost in balance with their diet. 
During this treatment no biochemical or clinical signs of dehydration were observed. 
Consequently, as stated by Anand et al., careful clinical assessment of patients is a reliable 
method for preventing diuretic-induced dehydration.19 Serum sodium normalized in most 
patients, as demonstrated in an earlier study in patients with severe CHF.6 However it must 
be stressed that combination with thiazides can result in severe hyponatremia, because of 
their lack of effect on urinary concentration.20 
We conclude that continuous furosemide adminstration is a safe, controllable and 
effective symptomatic treatment for patients with refractory CHF and should be the first 
step in the treatment of patients with CHF and diuretic resistance. When this strategy lacks 
effect, combination with diuretics that exert their effect in another part of the nephron, 
infusion with positive inotropics or hemofiltration could be helpful. 
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Summary 
In a study of cross-over randomized design in 12 healthy volunteers we compared the 
effect on magnesium excretion after administration of single oral doses offurosemide 40 
mg (F) and offurosemide 40 mg in combination with a single dose of triamterene 50 mg 
(F+T). F as well as F+T induced significant increases in volume, sodium and magnesium 
mean 24 h output as compared with 24 h renal excretion without medication. Addition of 
triamterene tofurosemide significantly reduced the 24 h potassium excretion, but did not 
attenuate the excretion of magnesium. The time to reach the maximum magnesium 
excretion rate after F as well as after F+T administration was similar to that of the sodium 
excretion rate. We conclude that triamterene does not inhibit the magnesiuric effects of 
furosemide in healthy male adults. 
Introduction 
Thiazides, thiazide-like as well as loop-diuretics cause loss of potassium and 
hypermagnesuria, but in most patients the serum concentrations of these electrolytes are 
normal and do not reflect the intracellular deficits [1-4]. Long-term treatment with these 
diuretics, especially in combination with inadequate dietary intake, has been postulated to 
cause overt hypomagnesemia [5, 6]. Hypomagnesemia in combination with hypokalemia 
has been associated with ventricular ectopic activity [7, 8] and could possibly contribute to 
sudden cardiac death [9]. 
In order to prevent hypomagnesemia caused by these diuretics, potassium-sparing 
diuretics such as amiloride, spironolactone and triamterene have been reported to be of 
value [10]. Most studies investigating the effect of the potassium-sparing agents on 
magnesium excretion were carried out with amiloride [11-13] or spironolactone [14]. In 
contrast to data on amiloride, there are conflicting results with respect to the magnesium 
sparing properties of triamterene alone [15, 16] and there are no reports of the effect on 
magnesium excretion of triamterene in combination with furosemide. Therefore, we 
performed a study in healthy volunteers to find out whether triamterene inhibits the 
magnesiuric effect of furosemide. 
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Materials and methods 
After approval of the protocol by the local ethical committee, 12 healthy non-smoking 
male volunteers gave their informed consent for the study. Their age ranged from 18-22 
years and their weight from 59.2 - 96.1 kg (Quetelet index; mean ± S.E.M.; 22.6 ± 0.9 
kg/m2, range: 17.1-26.9). All subjects had a normal medical history, physical examination, 
complete blood count and biochemistry. The study consisted of two treatment days, which 
were separated by drugfree washout periods of at least six days. On these treatment days 
they received in a randomized order a single oral dose of furosemide (40 mg) or 
furosemide(40 mg) and triamterene (50 mg). They received a diet containing 150 mEq 
sodium and 100 mEq potassium one day before and on each treatment day of the study. 
Total fluid intake on the pretreatment day was 2000 ml. They had to refrain from drinking 
alcohol, coffee and tea throughout the investigation days. On the day of the trial the drug 
tablets plus 150 ml of water were taken at 08.00 h after an overnight fast. Following 
administration there was a three hour fast for food. The amount of fluid ingested during the 
test days consisted of 150 ml each hour till 10 h after administration. The next 14 h they 
were allowed to drink 500 ml of water. So total fluid intake was 2000 ml in 24h. Urine was 
collected 0-24 h on the day before the trial and on the treatment day at intervals 0-1, 1-2, 
2-3, 3-4, 4-6, 6-8, 8-12 and 12-24 h after dosing. Urine was analyzed for sodium, 
potassium, magnesium and creatinine. Urine sodium and potassium were assayed with a 
flame photometer. Creatinine concentrations in urine and serum were determined using 
Jaffe's method. Endogenous creatinine clearances (E.C.C.) were calculated from creatinine 
values measured in serum and in 24-h urine samples. Magnesium in urine was measured 
using spectrophotometry (Hitachi 717). All samples were determined immediately after 
collection. The laboratory analyses were carried out by technicians who were unaware of 
the protocol being used. For the statistical evaluation, Student's r-tests for paired data were 
used at the 5% significance level. 
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Table I. Creatinine clearance, 24-hours urinary volume, solute excretions before and фег the oral administration of furosemide 
(40 mg) and furosemide (40 mg) + triamterene (50mg). Values are presented as means ± SEM. DM = difference of means, 
CI = confidence intervals. 
FUROSEMIDE 
Before treatment 
Afta treatment 
DM 
DM 95% CI 
FUROSEMIDE + 
TRIAMTERENE 
Before treatment 
After treatment 
DM 
DM 95% CI 
Creatinine 
detronce 
(mil min) 
132 ±5.8 
128 ±4 
-4 ±5.5 
- 16.8. 8.8 
124 ±4.4 
129 ±4 
4.5 ±4.1 
- 5. 14.2 
24 h urine 
volume 
(ml) 
1824 ±157 
2398 ±104 * ' 
556 ±172 
178.4, 934 
1722 ±139 
2511 ±129 ** 
728 ±221 
242, 1215 
U-Na 
(mmol) 
156 ±22 
259 ± 15 ** 
104 ±20 
59, 148.2 
142 ± 12 
302 ± 17 **# 
161 ±22 
111 ±210 
U-K 
(mmol) 
106 ±8 
120 ±7 
14 ± 8.3 
- 4.4, 32.4 
100 ±7 
104 ±5 * 
3.5 ±6. 5 
- 10.5, 17.8 
U-Mg 
(mmol) 
6.68 ± 0.36 
7.93 ± 0.55 * 
1.2 ± 0.6 
- 0.2, 2.6 
6.33 ± 0.46 
7.87 ± 0.48 * 
1.5 ± 0.3 
0.8, 2.3 
p< 0.001 vs before treatment 
pc 0.05 vs before treatment 
* pc 0.05 vs after treatment with furosemide 
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Figure 1. Mean (± s.e.mean) sodium and magnesium excretion rate (mmollh) after 
administration of a single oral dose offurosemide (40 mg, Ώ) and after the combination 
offurosemide (40 mg) and triamterene (50 mg,0 ). 
Results 
Table I shows the solute excretions on the day before and on the day after 
administration of furosemide alone and the combination of furosemide and triamterene. 
Baseline electrolyte excretions, as measured by 24 h urinary output on the day before each 
treatment day showed no differences. As expected there were significant increases in 
volume, sodium and magnesium mean 24 h output in all volunteers after administration of 
the drugs when compared with baseline values, while there was no difference in calculated 
endogenous creatinine clearance. Addition of triamterene to furosemide showed a 
significant increment of the sodium excretion. Moreover, a potassium sparing effect 
(p<0.05) but no magnesium sparing effect was observed. Figure 1 presents the time course 
of the magnesium and sodium excretion rate. We did not observe a difference in the time to 
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reach the maximum excretion of sodium (Tmax-Na[F]: 117.5 ± 24.6 min.) and magnesium 
(Tm«-Mg[F]: 112.5 ± 25.0 min.). Addition of triamterene had no influence on the time of 
the maximum excretion of both electrolytes (Tmax-Na[F+T]: 100 ± 8.5 min., Tman-
Mg[F+T]: 95 ± 8.9 min.). 
Discussion 
There are a number of possible explanations why in our study triamterene in 
combination with furosemide exerts no magnesium sparing effect. Firstly, in the animal 
studies examining the magnesium sparing properties of triamterene higher doses (25 mg/kg 
body weight) were used [15]. In a study in patients with essential hypertension, Jackson 
et al. found a dose-response of triamterene with respect to thiazide induced hypokalemia 
[17]. There may also be a similar dose response relation of triamterene with respect to 
furosemide induced hypermagnesuria. So it is possible that higher doses of triamterene are 
required to have any effect on urinary magnesium excretion. Secondly, in the animal 
experiments urine was collected only for 6 h after medication. However in our study the 
cumulative excretion of magnesium 6 h after furosemide or furosemide plus triamterene 
was not significantly different. Thirdly, clinical studies showing a magnesium sparing 
effect of triamterene were done on patients during long-term diuretic treatment. It has been 
speculated that addition of triamterene in this situation results in a rise in lymphocyte 
magnesium and an increase in skeletal muscle magnesium [18,19]. Finally magnesium is a 
highly bound intracellular cation so the failure of triamterene to attenuate urinary 
magnesium excretion is perhaps not altogether suprising. 
Realizing that approximately 50-60% of the filtered magnesium is reabsorbed at the 
thick ascending limb of the loop of Henle, while only 5% is reabsorbed in the distal tubule, 
it seems that direct blockade of magnesium reabsorption within the loop of Henle is the 
main cause for the magnesuria induced by loop diuretics. However Reyes & Leaiy found a 
delayed urinary magnesium flow as compared with sodium flow [20]. They suggest that a 
slow mechanism, possible endocrine in nature, may act in conjunction with direct blockade 
of magnesium reabsorption in the loop of Henle. We found that the time to reach the 
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maximum magnesium excretion rate was equal to the time to reach the maximum sodium 
excretion rate. Reyes & Leary collected urine in a greater dmespan so it is possible that the 
mathematical model they used misinterpreted the point of the maximum excretion rate of 
magnesium [21]. In our study addition of triamterene to furosemide had no influence on the 
maximum magnesium excretion rate nor on the 24 h urinary magnesium excretion. 
We conclude that triamterene in combination with furosemide does not have magnesium 
sparing properties in healthy male adults. 
Supported by a giant from Smith Kline & French b.v., Rijswijk, The Netherlands 
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Chapter Vili 
Summary and conclusions 

Since its introduction in the early sixties, the loop diuretic furosemide has often been 
used for the treatment of patients with congestive heart failure (CHF), hepatic/renal failure 
or nephrotic syndrome. However, despite a large amount of literature, no final conclusion 
can be drawn regarding the most efficient mode of administration and the maximum 
effective dose in patients with congestive heart failure. The aim of this thesis was to 
investigate the pharmacokinetics and pharmacodynamics of high dose furosemide in 
patients with congestive heart failure, the most efficient mode of furosemide administration 
and its implications with respect to CHF patients with diuretic resistance. These studies 
were prompted by the conclusions from the data described in chapter III on the effects of 
high dose furosemide in patients with refractory CHF. In addition pharmacodynamics of 
high dose furosemide in hemodialysis patients with residual diuresis was studied. 
In chapter I a general introduction is given on the role of furosemide in the treatment of 
congestive heart failure with special emphasis on diuretic resistance and diuretic efficiency. 
The introduction concludes with the objectives of this study. 
Previous studies suggest that malabsorption of furosemide, secondary to changes 
induced by CHF could be a cause of diminished response. Chapter II reports on the 
influence of the state (compensated or decompensated) of heart failure on absorption 
pharmacokinetics in nine patients with severe CHF (NYHA III-IV) after oral intake of the 
drug. Theoretically weight reduction could influence absorption kinetics and furosemide-
pharmacodynamics. Mean weight reduction between the decompensated and the 
compensated state was 12.0 kg. Individual furosemide plasma concentration-time curves 
could be adequately fitted to a one-compartment model with first order absorption and 
elimination kinetics. The absorption process in these patients could be divided in two 
distinct phases with different lag times. We did not find significant differences in 
pharmacokinetic parameters such as absorption half-life, elimination half-life, time to peak 
serum concentration, peak concentration itself and area under the plasma concentration-time 
curve, nor in pharmacodynamics. When these patients were decompensated the first 
absorption fraction was significantly smaller (31%) compared with the compensated 
state(65%). As a consequence a larger quantity of furosemide was initially delivered to the 
kidney in these patients when compensated; however, this had a minor influence on the 
onset and magnitude of diuresis. We concluded that the presence of massive edema in 
patients with congestive heart failure has only a minor -and read from this series of patients 
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clinically irrelevant- influence on the pharmacokinetics and the pharmacodynamics of high 
oral dose furosemide. However, it must be stressed that the pharmacokinetics and 
pharmacodynamics of furosemide are markedly altered in patients with both compensated 
and decompensated CHF compared with data obtained from healthy volunteers. 
In Chapter III the results of a retrospective study in 35 patients suffering from 
congestive heart failure (NYHA class III-IV) resistant to conventional diuretic treatment, 
which were treated with high dosages of furosemide, are reported. All patients had a 
reduced renal function (mean endogenous creatinine clearance 32 ml/min/l .73m2). Most 
patients were succesfully treated with high dose furosemide administered either orally, as 
an intravenous bolus dose or as continuous infusion. When this therapy eventually failed, 
patients (n=8) were treated with hemofiltration. Eighteen patients showed hyponatremia 
prior to high dose furosemide therapy which normalized during therapy (133-137 mmol/l in 
6 patients, 128-132 mmol/l in 9 and 123-127 mmol/l in 3 patients). Hypokalemia was 
observed in almost all patients and was succesfully treated with potassium sparing diuretics 
and/or potassium chloride supplementation. Serum uric acid levels were elevated in all 
patients, however attacks of gouty arthritis necessitated uricosuric therapy in only four 
cases. Dehydration, that required hospitalization, occurred in two outpatients. Tinnitus or 
hearing loss was not observed. 
Altogether, high dose furosemide can be effective in refractory congestive heart failure. 
Obviously, this treatment can only relief symptoms and long term prognosis remains highly 
unfavorable if heart transplantation is not a feasible solution. Ultimately, the quality and 
performance of the left ventricle determine patient survival. 
The short term and long term pharmacodynamic effects of daily oral administration of 
high dose furosemide (250 - 2000 mg) in patients on chronic hemodialysis with residual 
diuresis are described in chapter IV. In a short study, in which 10 patients (endogenous 
creatinine clearance 0.7-6.8 ml/min/l.73m2) were treated with 1000 mg of furosemide 
twice daily during 7 days, we observed a doubling of the 24h urinary volume and sodium 
excretion. During a one year follow-up of 13 patients, who used a fixed dose of 
furosemide (250-1000 mg), a gradual decrease in diuretic response with time was found 
obviously as a consequence of progression of the underlying renal disease. Plasma 
electrolytes showed no significant changes. Ototoxic side effects, which were monitored by 
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audiometrie controls, were not observed. The most important complication was sunlight 
induced bullous dermatitis (2 patients). It is concluded that high dose furosemide (up to 
1000 mg twice daily) is effective in patients on hemodialysis with residual renal function. 
However, it should be restricted to those patients who tend to important interdialytic 
overhydration despite residual diuresis. 
Some previous observations indicated that the time course of furosemide delivery into 
the renal tubule is an important determinant of volume diuresis and electrolyte excretions. 
In addition, there seems to be a correlation between the urinary excretion rate of furosemide 
and its diuretic efficiency. Data from literature shows a greater efficacy of divided 
furosemide doses when compared with an equivalent single dose. Theoretically, 
continuous infusion should be the most efficient and effective mode of administration. 
Chapter V describes a study that investigated the role of the time course of furosemide 
delivery and the influence of the furosemide excretion rate on diuretic efficiency. In this 
double-blind crossover study intravenous bolus administration of 40 mg of furosemide was 
compared with continuous infusion of furosemide (infusion rate 4 mg/h during 8 hours 
after an intravenous loading dose of 8 mg) in healthy volunteers. During the study days 
subjects were rehydrated with isovolumetric amounts of fluid. Volume diuresis and 
electrolyte excretions after 8 and 24 hours were significantly greater after continuous 
infusion, whereas total urinary furosemide excretion showed no differences. These 
findings strongly support the concept of the furosemide delivery rate into the renal tubule as 
an important determinant of diuretic efficiency. 
In chapter VI we used this concept in patients with CHF (NYHA III-IV) who were 
resistant to conventional therapy. Diuretic resistance was defined as a failure to lose weight 
and/or inappropriate urinary sodium excretion (< 50 mmol/24h) despite maximal 
conventional therapy, i.e. bed rest during 2-3 days, salt and water restriction, orally and 
intravenously administered furosemide in a dose of 250 mg a day, digoxin, and when 
possible an ACE-inhibitor. Continuous furosemide infusion was started with an infusion 
rate of 20 mg/h. Stepwise increase of the furosemide dose (up to a maximal cumulative 
dose of 3840 mg/day, i.e. 160 mg/h), according to a strictly defined protocol, resulted in a 
weight decrease and an improvement of the NYHA classification in all patients. The mean 
24h sodium output rose from 19 ± 16 mmol (n=10) on oral therapy with 250 mg 
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furosemide to 137 ± 85 mmol (n=8) during 80 mg/h and to 268 ± 124 mmol (n=3) on the 
maximal dose of 160 mg/h, while mean daily potassium output rose from 50 ± 21 mmol to 
78 ± 41mmol and to 82 ± 50 mmol respectively. Mild hypokalemia occurred in almost all 
patients and could be treated succesfully with oral potassium suppletion. It is concluded 
that continuous infusion of furosemide is a safe, controllable and effective treatment of 
patients with CHF and diuretic resistance. When this therapy eventually fails, combination 
with diuretics that exert their effect in another part of the nephron, infusion with positive 
inotropic drugs or hemofiltration can be of value. 
In patients with CHF, treated with diuretic agents, hypomagnesemia is a serious, 
sometimes life threatening side effect. In these patients treatment with potassium sparing 
agents is advocated. Most potassium sparing agents also show a magnesium sparing effect 
when used as a single drug. However combination with loop diuretics could diminish these 
effects. In chapter VII we describe a study in healthy volunteers in which the effect on the 
magnesium and potassium excretion of addition of triamterene to furosemide was 
investigated. This study demonstrated a potassium but not a magnesium sparing effect of 
triamterene. 
108 
General conclusion 
Altogether it is concluded that: 
• within the population of patients with CHF (NYHA III-IV), pharmacokinetics and 
pharmacodynamics of furosemide are hardly influenced by the state of (decom­
pensation (in terms of presence or absence of massive edema). 
• high dose furosemide (more than 1000 mg a day) can be effective in the treatment of 
patients with refractory CHF (NYHA III-IV) as well as in the management of 
hemodialysis patients with residual diuresis. 
• continuous infusion is the most efficient and effective mode of furosemide 
administration (in healthy volunteers). 
• continuous infusion of furosemide is effective in the treatment of patients with refiactOTy 
congestive heart failure (NYHA ІП-І ). Furosemide treatment with a maximal infusion 
rate of 160 mg/h can be given safely under careful clinical and electrolyte control. 
• triamterene in combination with furosemide has no magnesium sparing effect (in 
healthy volunteers). 
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Chapter IX 
Samenvatting en conclusies 

Het lisdiureticum furosemide wordt sinds het begin van de zestiger jaren gebruikt bij de 
behandeling van patiënten met decompensatio cordis, nefrotisch syndroom, levercirrhose 
of een nierfunctiestoomis. Ondanks vele studies, zowel verricht bij gezonde vrijwilligers 
als bij patiënten, is nog weinig bekend over de maximaal effectieve dosis bij patiënten met 
decompensatio cordis. Tevens ontbreken gegevens over de meest efficiënte 
toedieningswijze. 
De retrospectieve studie naar de effecten van hoge doses furosemide, die beschreven 
wordt in hoofdstuk III, is de aanleiding geweest tot nadere bestudering van de 
farmacokinetische en farmacodynamische effecten van hoge orale en intraveneuze doses 
furosemide bij patiënten met decompensatio cordis. Tevens was de klinische observatie dat 
patiënten die met een continu infuus behandeld werden een meer dan verwachte diurèse 
lieten zien aanleiding tot verder onderzoek, waarvan de resultaten in dit proefschrift 
weergegeven zijn. 
In hoofdstuk I wordt de plaats van furosemide in de behandeling van decompensatio 
cordis besproken. Tevens worden de begrippen diureticaresistentie en 'diuretic efficiency' 
nader toegelicht. Tot slot worden de vraagstellingen geformuleerd waarop dit proefschrift 
een antwoord hoopt te geven. 
Eerdere studies hebben gesuggereerd dat de absorptie van furosemide bij patiënten met 
decompensatio cordis kan verminderen als gevolg van darmwandoedeem, vertraagde 
maagontlediging, veranderingen in intestinale motiliteit en perfusie. Theoretisch zou 
behandeling van deze patiënten met diuretica de absorptiekinetiek en de farmacodynamiek 
van furosemide kunnen verbeteren. In hoofdstuk II worden de resultaten beschreven van 
een studie waarin de farmacokinetiek en -dynamiek is onderzocht bij dergelijke patiënten in 
gedecompenseerde toestand en vervolgens bij dezelfde patiënten nadat ze gecompenseerd 
waren. Het gemiddelde gewichtsverlies tussen de gedecompenseerde en de gecom-
penseerde toestand bedroeg 12 kg. De individuele plasma-concentratie curves in de tijd 
werden het best gemodelleerd in een één-compartiment-model met een I e orde absorptie- en 
climinatiekinetiek. Deze studie toonde minimale faimacokinetische en farmacodynamische 
veranderingen aan. Met name werden geen significante verschillen aangetoond in absorptie-
en eliminatiehalfwaardetijd, de maximale serumconcentratie, de tijd waarin de maximale 
serumconcentratie bereikt werd, oppervlakte onder de curve en in de farmacodynamiek. De 
absorptiekinetiek kon het best beschreven worden middels een model waarin de absorptie 
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in twee fasen werd verdeeld. De hoeveelheid furosemide die in de eerste fase werd 
geabsorbeerd was bij gecompenseerde patiënten significant hoger (65%) dan bij de 
gedecompenseerde patiënten (31%). Dit verschil in absorptie had evenwel nauwelijks 
invloed op het diuretisch effect. 
Samenvattend lijkt de (de)compensatietoestand van een patiënt met ernstig hartfalen 
nauwelijks -en, zoals gezien bij deze patiëntenserie geen klinisch relevante- invloed te 
hebben op de farmacokinetiek en farmacodynamiek van furosemide. Vergeleken met 
gezonde vrijwilligers zijn er echter zowel farmacokinetische als farmacodynamische 
veranderingen. 
In hoofdstuk III worden de resultaten beschreven van een retrospective studie naar de 
effecten van hoge doses furosemide, oraal toegediend (250-2500 mg), als intraveneuze 
bolus of als continu infuus (250-4000 mg) bij 35 patiënten met diureticaresistente 
decompensatio cordis (NYHA III-IV) met perifeer oedeem, niet behandelbaar met diuretica 
in de normale dosering. De meeste patiënten hadden een belangrijk verminderde nierfunctie 
(gemiddelde endogene creatinineklaring 32 ml/min/l .73m2). Bij alle patiënten trad een 
gewichtsdaling en een verbetering van symptomen op. Indien deze behandeling alsnog 
onvoldoende effect gaf werd overgegaan op behandeling met haemofiltratie (n=8). 
Hyponatriëmie, die vóór het begin van de hoge doses therapie aanwezig was (133-137 bij 
6, 128-132 bij 9 en 123-127 mmoiyi bij 3 patiënten), steeg tot normale waarden tijdens de 
behandeling. Bijwerkingen waren hypokaliëmie (31 patiënten), hyperuricaemie bij alle 
patiënten en bij 4 zich presenterend als jichtaanvallen. Bij 2 patiënten was heropname 
noodzakelijk wegens dehydratie. Tinnitus en gehoorsverlies werden niet gevonden. 
Concluderend: hoge doses furosemide zijn effectief bij de behandeling van patiënten 
met ernstige chronische decompensatio cordis en perifeer oedeem die niet reageren op de 
gangbare therapie. Van belang is te vermelden dat deze behandelingsmethode louter 
symptomatisch is en dat de uiteindelijke prognose bij deze patiënten wordt bepaald door de 
linkerventrikelfunctie. 
In hoofdstuk IV worden de korte en lange termijn effecten van hoge doses furosemide 
(250 mg - 2000 mg) beschreven bij dialysepatiënten met restdiurese. In de korte termijn 
studie waarin dialysepatiënten (n=10) met tweemaal daags 1000 mg furosemide werden 
behandeld was het mogelijk de diurèse en natriumexcretie te verdubbelen. Gedurende de 
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follow-up van een jaar bij 13 patiënten, die behandeld werden met een vaste furosemide-
dosis (2S0 - 1000 mg) trad er een geleidelijke vermindering van de diurèse op, die 
verklaard kon worden door de eveneens geleidelijke afname van de resterende nierfunctie. 
Een belangrijke bijwerking vormde het ontstaan van blaren op aan zonlicht blootgestelde 
lichaamsdelen. Ondanks langdurige behandeling met hoge doses furosemide traden geen 
belangrijke electrolietverschuivingen op. Ook gehoorsstoomissen, gecontroleerd middels 
audiometrie werden niet gevonden. Geconcludeerd wordt dat hoge doses furosemide 
effectief zijn bij hemodialysepatiënten met restdiurese. Echter, gezien de bijwerkingen 
bestaat er een beperkt indicatiegebied. 
De diuretische effecten van furosemide worden voor belangrijk deel bepaald door de 
snelheid waarmee en het tijdsverloop waarin furosemide wordt uitgescheiden in de 
proximale tubulus. Uit literatuurgegevens bleek dat spreiding van de furosemidedoses een 
groter diuretisch effect tot gevolg had. Theoretisch zou continue furosemidetoediening dan 
de meest effectieve en efficiënte toedieningswijze zijn. In hoofdstuk V worden de resultaten 
beschreven van een dubbelblinde crossover studie, venicht bij gezonde vrijwilligers, bijwie 
bolustoediening van 40 mg furosemide werd vergeleken met een continu infuus ( 8 mg 
oplaaddosis, vervolgens 4 mg per uur gedurende 8 uur). De vrijwilligers werden tijdens de 
studie gerehydreerd waarbij het volume van diurèse telkens werd terug gegeven middels 
een combinatie van infuus en orale toediening De excretie van electrolieten en het diuretisch 
volume was bij het continue furosemide infuus significant groter dan bij bolustoediening, 
zowel na 8 uur als na 24 uur. Deze resultaten laten zien dat de snelheid van de furosemide 
uitscheiding in de proximale tubulus en het tijdsbestek waarin dit plaats vindt inderdaad een 
belangrijke bijdrage levert aan het totale diuretische effect. 
Dit concept hebben wij vervolgens toegepast bij 10 patiënten met decompensatio cordis 
(NYHA III-IV) een geschat oedeem van meer dan 5 kg en diureticaresistentie. 
Diureticaresistentie werd alsvolgt gedefinieerd: onvoldoende gewichtsverlies en natriurese 
ondanks maximaal gebruikelijke decompensatietherapie (i.e.; bedrust gedurende 2-3 dagen, 
vocht en zoutbeperking, orale en intraveneuze behandeling met 250 mg furosemide, 
digoxine en indien mogelijk behandeling met een ACE-inhibitor. De patiënten werden 
behandeld met een continu furosemide-infuus waarbij gestart werd met een dosis van 20 
mg per uur. Vervolgens werd op geleide van lichamelijk onderzoek, gewichtsverlies en 
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diurèse de dosis geleidelijk verhoogd volgens een protocol. Nadat de patiënten 
gecompenseerd waren werd deze behandeling vervangen door orale toediening. De 
maximaal toegediende dosis bedroeg 160 mg per uur. In hoofdstuk VI worden de 
resultaten van dit onderzoek weergegeven. Bij al deze (geselecteerde) patiënten trad een 
gewichtsdaling en een verbetering van symptomen op. De natriumuitscheiding steeg van 19 
±16 mmol/24uur tijdens orale therapie met 250 mg furosemide tot 137 ± 85 mmol/24uur 
tijdens continue infuus met 80 mg/uur en tot 268 ± 124 mol/24uur bij de maximale dosis 
van 160 mg/uur. De dagelijkse kaliumuitscheiding steeg respectievelijk van 50 ± 21 tot 78 
± 41 en tot 82 ± 50 mmol. De belangrijkste bijwerking bestond uit hypokaliëmie die goed 
te behandelen was met orale kaliumsuppletie of met kaliumsparende diuretica. Continue 
furosemidetoediening lijkt dus een aanwinst bij de behandeling van diureticaresistente 
decompensatio cordis. Als deze therapie geen effect heeft is combinatie met diuretica die 
een ander aangrijpingspunt in de nier hebben een optie. Hierbij kunnen zich echter klinisch 
belangrijke electrolytstoomissen voordoen zoals ernstige hypokaliëmie en hyponatriëmie. 
Andere behandelings-mogelijkheden zijn dobutamine-infusie of haemofiltratie. 
H)pomagnesiëmie kan ontstaan bij langdurige behandeling met lisdiuretica als gevolg 
van de toegenomen renale magnesiumexcretie. Dit kan met name bij patiënten met 
decompensatio cordis een verhoogde kans op ntmestoomissen veroorzaken. Teneinde de 
magnesiumexcretie, veroorzaakt door lisdiuretica, te verminderen wordt behandeling met 
kaliumsparende diuretica aanbevolen. In de literatuur bestaan echter tegenstrijdige berichten 
over de magnesiumsparende effecten van het kaliumsparende diureticum triamtereen in 
combinatie met furosemide. In hoofdstuk VII staan de resultaten beschreven van een studie 
verricht bij vrijwilligers waarin het magnesium- en kaliumsparende effect van triamtereen in 
combinatie met furosemide werd onderzocht. Deze studie toonde aan dat triamtereen in 
combinatie met furosemide wel een kaliumsparend effect doch geen magnesiumsparend 
effect heeft. 
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Conclusies 
De conclusies die kunnen worden getrokken uit de in dit proefschrift beschreven 
onderzoeken zijn de volgende: 
• de farmacokinetiek en farmacodynamiek van furosemide bij patiënten met ernstige 
decompensatio cordis (NYHA III-IV) en meer dan 5 kg perifeer oedeem wordt 
nauwelijks beïnvloed door de toestand van (de)compensatie van deze patiënten. 
• hoge doses furosemide (meer dan 1000 mg/24uur) kunnen effectief zijn bij de 
behandeling van patiënten met ernstige decompensatio cordis (NYHA ПІ-І ) en meer 
dan 5 kg perifeer oedeem evenals bij haemodialysepatiënten met restdiurese. 
• continue infusie van furosemide is efficiënter en effectiever dan intraveneuze bolus-
toediening (bij gezonde vrijwilligers). 
• continue furosemidetoediening lijkt een effectieve behandeling bij patiënten met 
decompensatio cordis, perifeer oedeem en diureticaresistentie. Hierbij is een maximale 
infusiesnelheid van 160 mg/uur veilig en effectief gebleken. Van belang hierbij is een 
nauwkeurige klinische controle van de patiënt en zijn electrolieten. 
• triamtereen heeft in combinatie met furosemide een kaliumsparend maar geen 
magnesi umsparend effect (bij gezonde vrijwilligers). 
117 

DANKWOORD 
Bij de totstandkoming van dit proefschrift zijn velen direct of indirect betrokken geweest. 
Allereerst hecht ik eraan de naam van wijlen prof. dr. C.A.M, van Ginneken met eerbied te 
gedenken. 
Zonder iemand tekort te willen doen wil ik verder met name noemen: 
Alle patiënten en proefpersonen die aan de verschillende onderzoeken hebben meegewerkt. 
Dr. P.P.G. Gerlag, beste Paul, mede dankzij jouw stimulerende invloed, enthousiasme en 
doorzettingsvermogen is het onderzoek dat grotendeels zijn oorsprong vond in het 
St-Joseph Ziekenhuis (toen nog in Eindhoven) uitgemond in dit proefschrift. Mijn oprechte 
dank hiervoor. 
Dr. J.S. Bos, beste Hans, jij was een belangrijke schakel in de contacten met de afdeling 
cardiologie en het "leveren" van patiënten. 
Mevr. С Vonk, beste Chris, hartelijk dank voor je nauwgezette berichtgeving omtrent de 
Eindhovense patiënten. 
De zusters en broeders van de afdelingen cardiologie en inwendige geneeskunde van het St. 
Joseph ziekenhuis te Veldhoven en van het Academisch Ziekenhuis te Nijmegen dank ik 
voor hun hulp bij het nauwkeurig verzamelen van de vele bloed- en urinemonsters. De 
aluminiumfolie kan voorlopig opgeborgen worden! 
De Heer Y. Tan, beste Yuen, zelden heb ik iemand ontmoet die met zoveel zorg en 
accuratesse serumconcentraties bepaalt. Dank voor de vele furosemidebepalingen die je met 
oosters geduld hebt verricht. 
Mevr. G. Wessel-Hoogstraaten, beste Gemma, dank voor de secretariële ondersteuning. 
Cees Nicolasen heeft met vakmanschap vele figuren getekend. 
De medewerkers van het centraal klinisch-chemisch laboratorium (hoofd: dr. J. Willems) 
bepaalden de vele bloed- en urinemonsters. Tevens wil ik alle medewerkers van de Kliniek 
voor Inwendige Ziekten bedanken voor de collegiale sfeer en stimulerende samenwerking 
gedurende de afgelopen jaren. Tenslotte bedank ik mijn ouders voor de gelegenheid, die zij 
mij geboden hebben om dit te kunnen bereiken. 
Leia, het karwei is geklaard. Dank voor je vaak succesvolle pogingen mij te laten beseffen 
dat het maken van een proefschrift niet altijd zaligmakend is. 
119 

CURRICULUM VITAE 
De schrijver van dit proefschrift werd 27 september 1953 in Bemmel geboren. Vanaf 1965 
bezocht hij het St. Ignatius college te Amsterdam, en behaalde er in 1971 het diploma 
gymnasium B. Hij studeerde geneeskunde aan de Vrije Universiteit te Amsterdam, waar het 
doctoraal examen werd afgelegd in 1977 en het artsexamen in 1979. In datzelfde jaar tot 
januari 1981 was hij werkzaam als arts-assistent inteme geneeskunde in het Burger-
ziekenhuis te Amsterdam (hoofd: dr. S.P. ten Holt). Daarna was hij gedurende een jaar 
werkzaam als arts-assistent kindergeneeskunde in de praktijk van A.A.J. Broekman en J. 
Vonk, kinderartsen, Juliana Ziekenhuis, respectievelijk St. Josef Ziekenhuis te Zaandam. 
Vervolgens was hij tot april 1982 werkzaam als arts-assistent röntgenologie in het 
Academisch Ziekenhuis Utrecht (hoofd: Prof. dr. J.B.A.C. Puylaert). 
In april 1982 werd de opleiding tot internist begonnen in het St. Lucas Ziekenhuis te 
Amsterdam (opleider: dr. H.B. Schrcuder). De opleiding werd voortgezet in het St. Joseph 
Ziekenhuis te Eindhoven (opleiders: dr. P.F.L.H.M. Deckers en dr. P.G.G. Gerlag). 
Registratie als internist vond plaats in 1987. 
Vanaf 1988 is hij deels werkzaam op de afdeling Klinische Farmacologie (hoofd: Prof. dr. 
F.W.G. Gribnau), deels op de afdeling Algemene Inwendige Geneeskunde van de Kliniek 
voor Inwendige Ziekten van het Academisch Ziekenhuis te Nijmegen (hoofd: Prof. dr. A. 
van 't Laar, later Prof. dr. J.W.M, van de Meer). 
121 



Stellingen 
behorende bij het proefschrift 
CLINICAL PHARMACOLOGICAL 
STUDIES ON FUROSEMIDE 
with special emphasis on the use of high doses 
J.J.M. van Meyel 
15 december 1992 
1 De farmacokinetiek en farmacodynamiek van furosenude zijn met afhankelijk van de 
(de)compensatietoestand van een patient met hartfalen 
(dit proefschrift) 
2 Bij patiënten met ernstige decompensatio cordis en diureücaresistentie is behandeling 
met een furosemidedosenng tot 3840 mg per 24 uur, toegediend middels een continu 
infuus effectief gebleken 
(dit proefschrift) 
3 Een continu furosenude infuus waarbij, na een oplaaddosis van 8 mg, gedurende 8 uur 
32 mg wordt toegediend is veel effectiever dan een zelfde totale hoeveelheid gegeven 
als bolusinjecöe bij gezonde vrijwilligers 
(dit proef schrift) 
4 Hyponatnemie bij patiënten met ernstige rechts decompensatio cordis is geen contra-
indicatie voor behandeling met lisdiuretica 
(dit proefschrift) 
5 Dat decompensatio cordis geen ziekte is maar een symptomencomplex wordt wel eens 
over het hoofd gezien 
6 De beschikbaarheid van een prettig leesbaar Journal of Negative Results zou veel 
overbodig onderzoek kunnen voorkomen 
7 Het is in principe mogelijk met behulp van echografisch onderzoek onderscheid te 
maken tussen een bactenele ileocaecitis en een appendicitis, waardoor een onnodige 
operatie voorkomen kan worden 
JBCM Puylaen et al. Ned Tijdschr Geneest. 1991.135 2176-80 
8. Er bestaat een grote discrepantie tussen de endoscopische en de histologische diagnose 
gastritis 
JJ M van Meyel et al. Medisch Journaal van het Si Joseph Ziekenhuis te Eindhoven, 
1989.18 149-153 
9 Het rendement en de diepgang van klinisch onderzoek zijn veelal gerelateerd aan de 
klinische ervaring van de onderzoeker 
10. Door het aantal formatieplaatsen van een afdeling afhankelijk te maken van de 
hoeveelheid voortgebrachte publicaties dreigt het gevaar dat klinisch werk in de 
verdrukking raakt. 
11. Het zou een goede zaak zijn wanneer 'pillenfabrikanten' meer aandacht aan de 
herkenbaarheid van hun produkten zouden besteden, zodat uitspraken als "U weet 
wel dokter, die kleine witjes voor het hart" tot het verleden gaan behoren. 
12. Het geven van een promotiefeest in "Het Witte Huis" vlak na de Amerikaanse 
verkiezingen lijkt op louter toeval te berusten. 
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